1
|
Kroshus E, Chrisman SPD, Hunt T, Hays R, Garrett K, Peterson A, Rivara FP, Chiampas G, Ramshaw D, Glang A. Stakeholder-Engaged Development of a Theory-Driven, Feasible, and Acceptable Approach to Concussion Education. Health Educ Behav 2024; 51:197-203. [PMID: 35703397 PMCID: PMC9751226 DOI: 10.1177/10901981221099886] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Concussion education is widely mandated and largely ineffective. Recent consensus guidance on concussion education asserts the importance of (1) theory-driven programming that targets the team as a system and (2) working with end users throughout the development process, and considering issues such as feasibility, acceptability, and sustainability. Consistent with this guidance, and in collaboration with youth sport stakeholders in two regions of the United States, we developed a novel approach to concussion education: Pre-game safety huddles. Safety huddles have the following two core components: (1) athletes, coaches, and other stakeholders come together before the start of each game and (2) opinion leaders (coaches, referees) affirm the importance of care seeking for suspected concussion. The aim of this article is to provide an overview of the collaborative process through which we refined the safety huddle concept into an acceptable and feasible intervention with potential for sustainable implementation in diverse youth sports settings with minimal resource demands. In describing our process and discussing challenges and opportunities, we hope to provide an example for others seeking to develop and implement injury prevention interventions in youth sports settings.
Collapse
Affiliation(s)
| | | | - Tamerah Hunt
- Georgia Southern University, Statesboro, GA, USA
| | | | | | - Alexis Peterson
- Centers for Disease Control and Prevention, Atlanta, GA, USA
| | | | | | | | - Ann Glang
- University of Oregon, Eugene, OR, USA
| |
Collapse
|
2
|
Daugherty J, Peterson A, Waltzman D, Breiding M, Chen J, Xu L, DePadilla L, Corrigan JD. Rationale for the Development of a Traumatic Brain Injury Case Definition for the Pilot National Concussion Surveillance System. J Head Trauma Rehabil 2024; 39:115-120. [PMID: 38039498 DOI: 10.1097/htr.0000000000000900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2023]
Abstract
BACKGROUND Current methods of traumatic brain injury (TBI) morbidity surveillance in the United States have primarily relied on hospital-based data sets. However, these methods undercount TBIs as they do not include TBIs seen in outpatient settings and those that are untreated and undiagnosed. A 2014 National Academy of Science Engineering and Medicine report recommended that the Centers for Disease Control and Prevention (CDC) establish and manage a national surveillance system to better describe the burden of sports- and recreation-related TBI, including concussion, among youth. Given the limitations of TBI surveillance in general, CDC took this recommendation as a call to action to formulate and implement a robust pilot National Concussion Surveillance System that could estimate the public health burden of concussion and TBI among Americans from all causes of brain injury. Because of the constraints of identifying TBI in clinical settings, an alternative surveillance approach is to collect TBI data via a self-report survey. Before such a survey was piloted, it was necessary for CDC to develop a case definition for self-reported TBI. OBJECTIVE This article outlines the rationale and process the CDC used to develop a tiered case definition for self-reported TBI to be used for surveillance purposes. CONCLUSION A tiered TBI case definition is proposed with tiers based on the type of sign/symptom(s) reported the number of symptoms reported, and the timing of symptom onset.
Collapse
Affiliation(s)
- Jill Daugherty
- Author Affiliations: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Injury Prevention, Atlanta, Georgia (Drs Daugherty, Peterson, Waltzman, Breiding, Chen, Xu, and DePadilla); and Department of Physical Medicine and Rehabilitation, The Ohio State University, Columbus (Dr Corrigan)
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Daugherty J, Waltzman D, Breiding M, Peterson A, Chen J, Xu L, Womack LS, DePadilla L, Watson K, Corrigan JD. Refinement of a Preliminary Case Definition for Use in Traumatic Brain Injury Surveillance. J Head Trauma Rehabil 2024; 39:121-139. [PMID: 38039496 DOI: 10.1097/htr.0000000000000901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2023]
Abstract
OBJECTIVE Current methods used to measure incidence of traumatic brain injury (TBI) underestimate its true public health burden. The use of self-report surveys may be an approach to improve these estimates. An important step in public health surveillance is to define a public health problem using a case definition. The purpose of this article is to outline the process that the Centers for Disease Control and Prevention undertook to refine a TBI case definition to be used in surveillance using a self-report survey. SETTING Survey. PARTICIPANTS A total of 10 030 adults participated via a random digit-dial telephone survey from September 2018 to September 2019. MAIN MEASURES Respondents were asked whether they had sustained a hit to the head in the preceding 12 months and whether they experienced a series of 12 signs and symptoms as a result of this injury. DESIGN Head injuries with 1 or more signs/symptoms reported were initially categorized into a 3-tiered TBI case definition (probable TBI, possible TBI, and delayed possible TBI), corresponding to the level of certainty that a TBI occurred. Placement in a tier was compared with a range of severity measures (whether medical evaluation was sought, time to symptom resolution, self-rated social and work functioning); case definition tiers were then modified in a stepwise fashion to maximize differences in severity between tiers. RESULTS There were statistically significant differences in the severity measure between cases in the probable and possible TBI tiers but not between other tiers. Timing of symptom onset did not meaningfully differentiate between cases on severity measures; therefore, the delayed possible tier was eliminated, resulting in 2 tiers: probable and possible TBI. CONCLUSION The 2-tiered TBI case definition that was derived from this analysis can be used in future surveillance efforts to differentiate cases by certainty and from noncases for the purpose of reporting TBI prevalence and incidence estimates. The refined case definition can help researchers increase the confidence they have in reporting survey respondents' self-reported TBIs as well as provide them with the flexibility to report an expansive (probable + possible TBI) or more conservative (probable TBI only) estimate of TBI prevalence.
Collapse
Affiliation(s)
- Jill Daugherty
- Author Affiliations: Division of Injury Prevention, Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control (NCIPC), Atlanta, Georgia (Drs Daugherty, Waltzman, Breiding, Peterson, Chen, Xu, Womack, and DePadilla); United States Public Health Service, Commissioned Corps, Washington, District of Columbia (Drs Breiding and Womack); Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention & Health Promotion, Division of Population Health, Atlanta, Georgia (Dr Watson); and Department of Physical Medicine and Rehabilitation, The Ohio State University, Columbus (Dr Corrigan)
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Judkins J, Moore B, Stone E, Welsh A, Carbon G, Rendell B, Peterson A. Pilot investigation of an activity-based approach to building hardiness. BMJ Mil Health 2023; 169:350-354. [PMID: 34413115 DOI: 10.1136/bmjmilitary-2020-001661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 08/13/2021] [Indexed: 11/03/2022]
Abstract
BACKGROUND The purpose was to describe an activity-based psychological hardiness training programme delivered by an occupational therapist and examine its acceptability and effectiveness in improving hardiness. METHOD Participants (N=28) completed the 6-hour programme, which included pre/post-programme completion of the Dispositional Resilience Scale-15 (DRS-15) and a Program Evaluation Form. Paired t-tests were used to determine differences between pre-training and post-training scores on the DRS-15. RESULTS Results showed a significant increase (p<0.05) in total hardiness, commitment, and control scores on the DRS-15 from pre-training to post-training and good-excellent ratings for all categories on the Program Evaluation Form. CONCLUSIONS This programme evaluation described an occupational therapist's role in providing an activity-based psychological hardiness training programme and provided preliminary support for the acceptability of an activity-based approach to training psychological hardiness for service members.
Collapse
Affiliation(s)
- Jason Judkins
- Military Performance Department, US Army Research Institute of Environmental Medicine, Natick, Massachusetts, USA
| | - B Moore
- Department of Psychological Science, Kennesaw State University, Kennesaw, Georgia, USA
| | - E Stone
- 5-20 Infantry Battalion, 1-2 Stryker Brigade Combat Team, Joint Base Lewis-McChord, Washington, USA
| | - A Welsh
- US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - G Carbon
- Center for Army Analysis, Fort Belvior, Virginia, USA
| | - B Rendell
- AFROTC Detachment 842, University of Texas at San Antonio, San Antonio, Texas, USA
| | - A Peterson
- Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| |
Collapse
|
5
|
Kroshus E, Chrisman SPD, Glang A, Hunt T, Hays R, Lowry S, Peterson A, Garrett K, Ramshaw D, Hafferty K, Kinney E, Manzueta M, Steiner MK, Bollinger BJ, Chiampas G, Rivara FP. Concussion education for youth athletes using Pre-Game Safety Huddles: a cluster-randomised controlled trial. Inj Prev 2023; 29:22-28. [PMID: 36113984 PMCID: PMC9877103 DOI: 10.1136/ip-2022-044665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Accepted: 08/21/2022] [Indexed: 01/29/2023]
Abstract
OBJECTIVES Determine whether Pre-Game Safety Huddles, a novel and low-resource approach to concussion education, increase the expected likelihood of concussion reporting for youth athletes. METHODS A cluster-randomised trial compared Safety Huddles to usual care. Safety Huddles bring together athletes and coaches from both teams before the start of each game for coaches to briefly affirm the importance of speaking up if a concussion is suspected. Participants were athletes from 22 competitive community-based American football and girls and boys soccer teams (ages 9-14), and randomisation into intervention or control occurred at the level of the bracket (group of teams that compete against each other during the regular season). The primary outcome was expected likelihood of reporting concussion symptoms to the coach, measured via validated athlete survey at the beginning and end of the season. RESULTS Of 343 eligible participants, 339 (99%) completed baseline surveys and 303 (88%) completed surveys at season end. The mean (SD) age was 11.4 (1.1) years, 26% were female soccer athletes, 27% were male soccer athletes and 47% were football athletes. In adjusted analyses accounting for baseline values and clustering by sport and team via random effects, expected likelihood of concussion reporting at the end of the season was significantly higher in the intervention group compared to controls (mean difference=0.49, 95% CI 0.11 to 0.88; Cohen's d=0.35). CONCLUSIONS AND RELEVANCE Pre-Game Safety Huddles increased the expected likelihood of athletes reporting concussion symptoms. While further study is warranted, sport organisations should consider this approach a promising low-resource option for improving concussion safety in their setting. TRIAL REGISTRATION NUMBER NCT04099329.
Collapse
Affiliation(s)
- Emily Kroshus
- Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA .,Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, Washington, USA
| | - Sara P D Chrisman
- Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA,Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Ann Glang
- Center of Brain Injury, Research and Training, University of Oregon, Eugene, Oregon, USA
| | - Tamerah Hunt
- Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, Georgia, USA
| | - Rachel Hays
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Sarah Lowry
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Alexis Peterson
- National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Kimberly Garrett
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Dane Ramshaw
- Center of Brain Injury, Research and Training, University of Oregon, Eugene, Oregon, USA
| | - Kiana Hafferty
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Erin Kinney
- Oregon Health & Science University School of Medicine, Portland, Oregon, USA
| | - Maria Manzueta
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Mary Kathleen Steiner
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Beth J Bollinger
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| | | | - Frederick P Rivara
- Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA,Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle, Washington, USA
| |
Collapse
|
6
|
Singh N, Peterson A, Baraff A, Chung S, Bhatti P, Coffey D, Barton J, LI C, Smith N, Weiss N. POS1422 USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND RISK OF MULTIPLE MYELOMA IN PERSONS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundBiologic therapies used in the management of rheumatoid arthritis (RA) target several cytokines that have been implicated in the pathogenesis of multiple myeloma (MM). Yet little is known about the association between use of biologic or targeted synthetic disease modifying anti-rheumatic drugs (b or tsDMARDs) in RA and the incidence of MM.ObjectivesOur objective was to estimate the association between b/tsDMARD use and the risk of MM among persons with RA using Veterans Health Administration (VHA) data. We hypothesized that b-/tsDMARD use is associated with a lower incidence of MM compared with conventional synthetic DMARDs (csDMARDs).MethodsIn this retrospective cohort study, we identified patients >18 years of age diagnosed with RA in any United States VHA facility from 1/1/2002 and 12/31/2018. All patients met the following inclusion criteria: 1) two or more International Classification of Diseases Version 9 or 10 (ICD9 or ICD10) codes for RA at least 7 days apart but no more than 365 days apart 2) a prescription for a csDMARD within 90 days of the first RA diagnosis 3) one inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating a regular user of VHA). Medication data was derived from the outpatient prescription fills, bar coded medication administration (BCMA), and intravenous (IV) data domains. The csDMARDs included in these analyses were: methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. The bDMARDs included were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics such as tocilizumab, rituximab, abatacept, and biosimilars; tsDMARD was tofacitinib. Patients with MM before the diagnosis of RA were excluded. Incident MM was determined by 1 or more ICD9/10 code or ICD-oncology codes. Multivariable Cox proportional hazards model were performed to estimate the hazard ratio for developing MM among those during and following the use of a b-/tsDMARD relative to b-/tsDMARD-naïve persons adjusting for age, gender, race, and ethnicity.Results27,540 veterans with RA met study eligibility criteria, of whom 8,322 (30%) had taken a b-/tsDMARD. Over the study period there were 77 incident MM over a total of 192,000 person years. There were 55 events in users of csDMARDs, an incidence rate (IR) of 0.40 (95% CI 0.30-0.52) per 1000 person-years and 22 in persons currently or formerly using b-/tsDMARDs (IR 0.41, 0.25-0.61 per 1000 person years). The unadjusted hazard ratio for MM following bDMARD use relative to csDMARD only use was 1.04 (0.63, 1.73), which increased to 1.28 (0.76, 2.16) after adjusting for demographic characteristics (Table 1).Table 1.Multivariable Cox proportional hazards model for association between use of disease modifying anti-rheumatic drugs and incident multiple myeloma.Clinical characteristicHazards ratio (95% CI)csDMARDReferenceb-/tsDMARD use1.28 (0.76-2.16)Age*1.04 (1.02-1.07)Female0.58 (0.20-1.62)RaceReferenceWhite2.11 (1.15-3.86)Black0.70 (0.10-5.08)OtherHispanic Ethnicity0.71 (0.17-2.92)Abbreviations: b-/tsDMARD- biologic or targeted synthetic disease modifying anti-rheumatic drug; CI: confidence interval*Hazards ratio reflects risk per every 1-year increase in ageModel adjusted for age, gender, race, and ethnicityConclusionIn this nationwide VA study, we did not observe an association between bDMARD use and the incidence of MM. Of note, the median interval from initiation of a bDMARD to the end of follow-up was approximately 5.8 years, which does not allow for an examination of a possible longer term influence.Disclosure of InterestsNone declared
Collapse
|
7
|
Singh N, Peterson A, Baraff A, Bhatti P, Gopal A, Smith N, Barton J, Curtis J, LI C, Weiss N. POS1434 USE OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF LYMPHOMA IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundEpidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) contribute to lymphoma development (1). Whether the decrease in inflammatory burden seen with use of biologic or targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs or tsDMARDs) translates into a lower risk of lymphoma in RA needs to be studied.ObjectivesThe objective of our study was to examine the effect of administration of b/tsDMARDS on the incidence of lymphoma relative to conventional synthetic DMARDs (csDMARDs) in an inception cohort of Veterans with RA.MethodsWe identified patients >18 years of age diagnosed with RA in any US Veterans Affairs (VA) facility from 1/1/2002 and 12/31/2018 using the VA Corporate Data Warehouse (CDW). To be included, each patient was required to meet the following criteria: 2+ RA diagnostic codes at least 7 days apart but no more than 365 days apart; 2) a prescription for a csDMARD within 90 days of the first RA diagnosis; and 3) an inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating they are a regular user of the VA). The csDMARDs included in these analyses were: methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. The bDMARDs included were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics such as tocilizumab, rituximab, abatacept, and biosimilars; tsDMARD was tofacitinib. Patients with prevalent lymphoma were excluded. Lymphoma diagnoses were identified using International Classification of Diseases Version 9, 10 and Oncology (ICD9, ICD10, ICDO) codes.We used marginal structural models as described by Hernan et al (2) and time-varying Cox models to control for confounding by indication while evaluating this association. We adjusted for baseline demographics (age, sex, race, ethnicity, year of cohort entry, rheumatology visits), and time-varying CRP and time-varying Rheumatoid Disease Comorbidity Index (RDCI) (3) to control for confounding.Results27,421 Veterans with RA met our eligibility criteria. Most of the Veterans (56%) were in the age range 61-80 years old; 89% male, 76% White, 14% African American. 8,225 (30%) patients were treated with a b-/tsDMARD. The crude incidence rates were 1.71 (95% CI 1.5-1.94) per 1000 person-years for those only on csDMARDs and 1.78 (95% CI 1.44-2.18) for patients during or following use of a b/tsDMARDs. After adjustment with both time-fixed and time-varying covariates using marginal structural models, the incidence of lymphoma was not different between patients who did and did not use a b/tsDMARD (hazard ratio=1.06, 95% CI= 0.82-1.37) (Table 1).Table 1.Estimates of Effect of bDMARD or tsDMARD use on Lymphoma relative to use of csDMARDsMarginal Structural Models; adjusted for:@Demographics1.04(0.80, 1.34)#Demographics + CRP1.06(0.82, 1.37)* per 1000 person-years@Demographics = age, gender, race, ethnicity, rheumatology visits, and year of cohort entry#Adjusts for CRP, baseline rheumatology visits (yes/no) and RDCI.CRP = C-Reactive Protein, RDCI = Rhematic Disease Comorbidity Index, CI = Confidence Interval, b/tsDMARD = biologic or targeted synthetic DMARD, csDMARD = conventional synthetic DMARDConclusionIn this large study using the nationwide VA data, we did not observe an association between the use of b/ts DMARDs and an increased risk of lymphoma.References[1]Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692-701.[2]Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-60.[3]England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis care & research. 2015;67(6):865-72.Disclosure of InterestsNone declared
Collapse
|
8
|
Peterson A, Gabella BA, Johnson J, Hume B, Liu A, Costich JF, Hathaway J, Slavova S, Johnson R, Breiding M. Multisite medical record review of emergency department visits for unspecified injury of head following the ICD-10-CM coding transition. Inj Prev 2021; 27:i13-i18. [PMID: 33674328 PMCID: PMC7948189 DOI: 10.1136/injuryprev-2019-043517] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 08/04/2020] [Accepted: 08/07/2020] [Indexed: 11/17/2022]
Abstract
Introduction In 2016, a proposed International Classification of Diseases, Tenth Edition, Clinical Modification surveillance definition for traumatic brain injury (TBI) morbidity was introduced that excluded the unspecified injury of head (S09.90) diagnosis code. This study assessed emergency department (ED) medical records containing S09.90 for evidence of TBI based on medical documentation. Methods State health department representatives in Maryland, Kentucky, Colorado and Massachusetts reviewed a target of 385 randomly sampled ED records uniquely assigned the S09.90 diagnosis code (without proposed TBI codes), which were initial medical encounters among state residents discharged home during October 2015–December 2018. Using standardised abstraction procedures, reviewers recorded signs and symptoms of TBI, and head imaging results. A tiered case confirmation strategy was applied that assigned a level of certainty (high, medium, low, none) to each record based on the number and type of symptoms and imaging results present in the record. Positive predictive value (PPV) of S09.90 by level of TBI certainty was calculated by state. Results Wide variation in PPV of sampled ED records assigned S09.90: 36%–52% had medium or high evidence of TBI, while 48%–64% contained low or no evidence of a TBI. Loss of consciousness was mentioned in 8%–24% of sampled medical records. Discussion Exclusion of the S09.90 code in surveillance estimates may result in many missed TBI cases; inclusion may result in counting many false positives. Further, missed TBI cases influenced by incidence estimates, based on the TBI surveillance definition, may lead to inadequate allocation of public health resources.
Collapse
Affiliation(s)
- Alexis Peterson
- National Center for Injury Prevention and Control-Division of Injury Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Barbara A Gabella
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Jewell Johnson
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Beth Hume
- Massachusetts Department of Public Health, Boston, Massachusetts, USA
| | - Ann Liu
- Center for Environmental & Occupational Epidemiology, Environmental Health Bureau, Maryland Department of Health, Baltimore, Maryland, USA
| | - Julia F Costich
- Kentucky Injury Prevention and Research Center, University of Kentucky, Lexington, Kentucky, USA
| | - Jeanne Hathaway
- Injury Surveillance Program, Massachusetts Department of Public Health, Boston, Massachusetts, USA
| | | | - Renee Johnson
- National Center for Injury Prevention and Control-Division of Injury Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Matt Breiding
- National Center for Injury Prevention and Control-Division of Injury Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
9
|
Aminian M, Ghosh T, Peterson A, Rasmussen AL, Stiverson S, Sharma K, Kirby M. Early prognosis of respiratory virus shedding in humans. Sci Rep 2021; 11:17193. [PMID: 34433834 PMCID: PMC8387366 DOI: 10.1038/s41598-021-95293-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Accepted: 07/23/2021] [Indexed: 11/24/2022] Open
Abstract
This paper addresses the development of predictive models for distinguishing pre-symptomatic infections from uninfected individuals. Our machine learning experiments are conducted on publicly available challenge studies that collected whole-blood transcriptomics data from individuals infected with HRV, RSV, H1N1, and H3N2. We address the problem of identifying discriminatory biomarkers between controls and eventual shedders in the first 32 h post-infection. Our exploratory analysis shows that the most discriminatory biomarkers exhibit a strong dependence on time over the course of the human response to infection. We visualize the feature sets to provide evidence of the rapid evolution of the gene expression profiles. To quantify this observation, we partition the data in the first 32 h into four equal time windows of 8 h each and identify all discriminatory biomarkers using sparsity-promoting classifiers and Iterated Feature Removal. We then perform a comparative machine learning classification analysis using linear support vector machines, artificial neural networks and Centroid-Encoder. We present a range of experiments on different groupings of the diseases to demonstrate the robustness of the resulting models.
Collapse
Affiliation(s)
- M Aminian
- Department of Mathematics and Statistics, California State Polytechnic University, Pomona, CA, USA
| | - T Ghosh
- Department of Computer Science, Colorado State University, Fort Collins, CO, 80524, USA
| | - A Peterson
- Department of Mathematics, Colorado State University, Fort Collins, CO, 80524, USA
| | - A L Rasmussen
- Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK, Canada.,Center for Global Health Science and Security, Georgetown University Medical Center, Washington, DC, USA
| | - S Stiverson
- Department of Mathematics, Colorado State University, Fort Collins, CO, 80524, USA
| | - K Sharma
- Department of Computer Science, Colorado State University, Fort Collins, CO, 80524, USA
| | - M Kirby
- Department of Mathematics, Colorado State University, Fort Collins, CO, 80524, USA. .,Department of Computer Science, Colorado State University, Fort Collins, CO, 80524, USA.
| |
Collapse
|
10
|
Singh N, Peterson A, Baraff A, Korpak A, Vaughan-Sarrazin M, Smith N, Curtis J, Weiss N. POS0287 USE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RELATION TO THE RISK OF LYMPHOMA: A COHORT STUDY OF US VETERANS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) contribute to lymphoma development. However, the association of the use of biologic disease modifying anti-rheumatic drugs (bDMARDs) in patients with RA on lymphoma risk needs further evaluation.Objectives:Examine the effect of administration of bDMARDS on the incidence of lymphoma in an inception cohort of RA.Methods:We identified patients diagnosed with RA in any US Veterans Affairs (VA) facility from 1/1/2002 and 12/31/2018 using the Veteran’s Health Administration (VHA) databases. To be included, each patient was required to meet the following criteria: 1) 2+ RA diagnostic codes at least 7 days apart but no more than 365 days apart 2) a prescription for a conventional synthetic DMARD (csDMARD) within 90 days of the first RA diagnosis 3) One inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating they are a regular user of the VHA). We excluded patients for any of the following if they preceded the first RA diagnosis: 1) a prior single RA diagnostic code 2) a prescription for any DMARD medication 3) a concomitant diagnosis of another inflammatory arthritis (e.g. psoriatic arthropathy) 4) a diagnosis of lymphoma. Index date for the study is the date of the first qualifying RA diagnosis. Lymphoma diagnoses were identified through VHA records using the International Classification of Diseases-Oncology codes.Results:We identified 27,536 veterans with RA in the study period meeting the inclusion and exclusion criteria. Of these, 53% (n=14,705) were in the age range 60 to 80 years. The cohort was 89% male, 75.5% White, 13.7% African American. Over the study period, 1.2% (n=332) of the study population developed a lymphoma.Conclusion:Using the nationwide VHA we have identified a large inception cohort of patients with RA of whom 1.2% developed lymphoma over study follow-up. This data will be used in future analyses to produce estimates of the effect of biologic medications on lymphoma risk, adjusting for confounding by indication and other variables.Table 1.Baseline characteristics of the cohort based on bDMARD exposure statusCharacteristicbDMARD-naive (n= 19,095)bDMARD-exposed (n=8,441)Overall Lymphomas Age (years)171161 18-4046 40-606378 60-8010074 >8043 Males17,206 (90%)7,270 (86%)Race White14,150 (74%)6,627 (76%) Black2,674 (14%)1,090 (13%) Asian96 (0.5%)46 (0.5%) Native American or Pacific Islander371 (2%)187 (2.2%) Missing1,804 (9%)491 (6%)Acknowledgements:The work in this abstract is supported by Investigator Award from the Rheumatology Research Foundation to Dr Singh.Disclosure of Interests:None declared
Collapse
|
11
|
Villarreal B, Foster S, Hansen S, Brock M, Sanchez H, Gerwell K, Carrizales F, Peterson A, Pruiksma K, Mysliwiec V. 0860 Sleep Disorders In Female Military Personnel. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Sleep is an essential biological function and the disruption of sleep has deleterious consequences. Military personnel experience unique stressors related to their service, elevating the risk of developing sleep disorders. The etiologies and impact of sleep disorders on military women’s health is poorly understood. This study is the first to prospectively assess whether military women with insomnia, obstructive sleep apnea (OSA), or comorbid insomnia and OSA (COMISA) have different gender roles, military service-associated factors, and biological characteristics than military men with the same disorders.
Methods
This is a prospective observational study of military personnel with sleep disturbances. The study will evaluate women and men matched for sleep disorder. Participants will complete an evaluation to include polysomnography (PSG), sleep questionnaires and validated clinical assessments of associated disorders of interest. The baseline demographics, questionnaire, and PSG results will be analyzed to assess for commonalities or differences between genders.
Results
We have enrolled 45 patients (24% female). Males had a higher BMI (29.1) than females (26). Males were also older (38) than females (35). The leading diagnosis in males was OSA (44%) and insomnia in females (64%). In males, the apnea-hypopnea index (AHI) was 11.3/hr, arousal index (ARI) was 20/hr, and sleep efficiency (SE) was 86.5%. Total sleep time (TST), wake after sleep onset (WASO), and sleep onset latency (SOL) were 364.6, 40.9, and 12.6 minutes, respectively. In females, the average AHI was 6.6/hr, ARI was 15/hr, and SE was 87.2%. Their TST, WASO, and SOL were 359, 44, and 12.6 minutes, respectively.
Conclusion
Military personnel are at increased risk of sleep disorders. Literature comparing male and female characteristics and sleep disorders is scarce. In this study, baseline demographics were similar in both groups but insomnia was the leading diagnosis for women. This emphasizes the importance of adequate recognition and treatment of insomnia in this group.
Support
This study is supported by the Defense Health Agency, Defense Medical Research and Development Program, Clinical Research Intramural Initiative for Military Women’s Health.
Collapse
Affiliation(s)
- B Villarreal
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - S Foster
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - S Hansen
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - M Brock
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - H Sanchez
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - K Gerwell
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - F Carrizales
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - A Peterson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - K Pruiksma
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - V Mysliwiec
- San Antonio Military Healthcare System, Lackland AFB, TX
| |
Collapse
|
12
|
Taylor D, Bunnell B, Calhoun C, Pruiksma K, Dietch J, Wardle-Pinkston S, Milanak M, Rheingold A, Simmons R, Peterson A, Morin C, Ruggiero K, Brim W, Dolan D, Wilkerson A. 1186 Developing And Testing A Web-based Provider Training For Cognitive Behavioral Therapy Of Insomnia. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Chronic insomnia is a common, debilitating disorder and a risk factor for significant medical morbidity, mental health problems, and workplace difficulties. Cognitive behavioral therapy for insomnia (CBT-I) is the gold standard treatment for insomnia. However, few providers are trained in CBT-I, in part due to a bottleneck in training availability and the time and cost associated with current training platforms. To address this training deficit, our team developed and evaluated CBTIweb.org, a web-based provider training course for CBT-I.
Methods
Feedback from alpha- and beta-testing of CBTIweb.org was collected and used to optimize course content and functionality. Then, a comparison study was conducted in which licensed providers were randomized to complete either the online CBTIweb.org course (n=21) or an in-person CBT-I training (n=23). During all phases of development, providers completed a Computer System Usability Questionnaire (CSUQ), investigator-developed website usability and content questionnaires, and pre/post-training competency assessments.
Results
Independent samples t-tests indicated significant improvements in CSUQ, and website usability and content questionnaires responses from alpha- to beta-testing (all ps < .05). Linear mixed-effects modeling revealed significant within-subject increases in knowledge acquisition (F(34.7) = 65.4, p < 0.001; baseline = 69% correct, post-training = 92% correct) when collapsed across in-person and web-based groups. The interaction group by time interaction was non-significant (F(34.7) = 1.7, p = 0.204), indicating similar gains in knowledge (i.e., equivalence) between the in-person and the CBTIweb.org training formats.
Conclusion
Alpha and beta testers of CBTIweb.org reported high levels of satisfaction while also noting areas for improvement, which were used to update the site. Findings suggest the final CBTIweb.org product successfully trained clinicians compared to an in-person workshop, given knowledge acquisition improvements. CBTIweb.org is an efficient and effective training platform for clinicians to gain knowledge and competence in the most effective treatment for insomnia.
Support
W81XWH-17-1-0165
Collapse
Affiliation(s)
- D Taylor
- University of Arizona, Tucson, AZ
| | - B Bunnell
- Medical University of South Carolina, Charleston, SC
| | - C Calhoun
- Medical University of South Carolina, Charleston, SC
| | | | - J Dietch
- University of North Texas, Denton, TX
| | | | - M Milanak
- Medical University of South Carolina, Charleston, SC
| | - A Rheingold
- Medical University of South Carolina, Charleston, SC
| | - R Simmons
- Medical University of South Carolina, Charleston, SC
| | | | - C Morin
- Laval University, Quebec, QC, CANADA
| | - K Ruggiero
- Medical University of South Carolina, Charleston, SC
| | - W Brim
- Center for Deployment Psychology, Bethesda, MD
| | - D Dolan
- Center for Deployment Psychology, Bethesda, MD
| | - A Wilkerson
- Medical University of South Carolina, Charleston, SC
| |
Collapse
|
13
|
Pruiksma KE, Hale W, Mintz J, Peterson A, Young-McCaughan S, Wilkerson A, Nicholson K, Dondanville K, Fina B, Borah E, Roache J, Litz BT, Bryan C, Taylor DJ. 0483 Predictors of Cognitive Behavioral Therapy for Insomnia (CBT) Outcomes in Active Duty U.S. Army Personnel. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Cognitive behavioral therapy for insomnia (CBTi) is well established as the first-line treatment for the management of chronic insomnia. Identifying predictors of response to CBTi should enable the field to efficiently utilize resources to treat those who are likely to respond and to personalize treatment approaches to optimize outcomes for those who are less likely to respond to traditional CBTi. Although a range of studies have been conducted, no clear pattern of predictors of response to CBTi has emerged.
Methods
The purpose of this study was to examine the impact and relative importance of a comprehensive group of pretreatment predictors of insomnia outcomes in 99 active duty service members who received in-person CBTi in a randomized clinical trial.
Results
Results indicated that higher levels of baseline insomnia severity and total sleep time predicted greater improvements on the Insomnia Severity Index (ISI) following treatment. Higher depression symptoms and a history of head injury predicted a worse response to treatment (i.e., smaller improvements on the ISI).
Conclusion
Clinically meaningful improvements, as measured by the reliable change index (RCI), were found in 59% of the sample. Over and above baseline insomnia severity, only depressive symptoms predicted this outcome. Future studies should examine if modifications to CBTi based on these predictors of response can improve outcomes.
Support
This study was conducted with support from the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program award W81XWH-10-1-0828 (PI: Dr Taylor).
Collapse
Affiliation(s)
- K E Pruiksma
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - W Hale
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - J Mintz
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - A Peterson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - S Young-McCaughan
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - A Wilkerson
- Medical University of South Carolina, Charleston, SC
| | - K Nicholson
- Carl R Darnall Army Medical Center, Fort Hood, TX
| | - K Dondanville
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - B Fina
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - E Borah
- University of Texas at Austin, Austin, TX
| | - J Roache
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - B T Litz
- Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA
| | - C Bryan
- University of Utah, Salt Lake City, UT
| | | |
Collapse
|
14
|
Miles SR, Pruiksma K, Slavish D, Nakase-Richardson R, Nicholson K, Wardle S, Young-McCaughan S, Resick P, Williamson D, Dondanville K, Litz B, Mintz J, Keane T, Peterson A, Taylor D. 1073 Sleep Disorders Contribute To Anger In Service Members With Posttraumatic Stress Disorder. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The emotion of anger and behavioral acts of aggression can lead to severe negative consequences, including family violence, legal charges, and death. Anger can be a symptom of posttraumatic stress disorder (PTSD), particularly in service members. Service members report difficulties managing their anger and trouble with the subsequent results. Factors that differentiate service members with PTSD who have anger related problems from those who do not are still unknown. Impaired sleep is associated with negative mood states in the general population and may be a risk factor for anger in those with PTSD. This project examines how sleep disorders commonly diagnosed in service members (i.e., obstructive sleep apnea and insomnia) relate to PTSD and anger.
Methods
Ninety-three service members with comorbid PTSD, insomnia, and nightmares (mean age = 35.86 years, SD = 8.38, 27% female, 45% white) completed polysomnography and other measures as part of a clinical trial. A multiple regression model examined how total Apnea Hypopnea Index (AHI), AHI during REM sleep, insomnia (Insomnia Severity Index), age, and race related to PTSD symptoms (Clinical Administered PTSD Scale-5: CAPS-5). A second multiple regression model examined the same variables’ associations with anger (Dimensions of Anger Reactions-5; DAR-5).
Results
More than a third of the sample (37%) met criteria for OSA (AHI scores>5) and 99% met criteria for insomnia (ISI>10). Total AHI and REM AHI were not associated with CAPS-5 scores or ISI. Across OSA and PSG indices, only greater REM AHI (b=.07, p<.05) and Insomnia (b=.43, p<.05) were positively associated with DAR-5 anger scores. Total AHI was unrelated to anger.
Conclusion
Elevated REM AHI and insomnia were associated with greater anger in service members with PTSD. Current treatments for anger are only moderately effective. Assessing and treating comorbid sleep disorders may reduce anger and enhance successful PTSD treatment.
Support
Consortium to Alleviate PTSD (W81XWH-13-2-0065), DVA (I01CX001136-01), GDHS (W91YTZ-13-C-0015) for DVBIC.
Collapse
Affiliation(s)
- S R Miles
- James A. Haley Veterans’ Hospital, Tampa, FL
| | - K Pruiksma
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - D Slavish
- University of North Texas, 76203, TX
| | | | - K Nicholson
- Carl D. Darnall Army Medical Center, Fort Hood, TX
| | - S Wardle
- The University of Arizona, Tucson, AZ
| | - S Young-McCaughan
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | | | | | - K Dondanville
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - B Litz
- VA Boston Healthcare System, Boston, MA
| | - J Mintz
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - T Keane
- VA Boston Healthcare System, Boston, MA
| | - A Peterson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - D Taylor
- The University of Arizona, Tucson, AZ
| |
Collapse
|
15
|
Ananthapavan J, Peterson A, Sacks G. Paying people to lose weight: the effectiveness of financial incentives provided by health insurers for the prevention and management of overweight and obesity - a systematic review. Obes Rev 2018; 19:605-613. [PMID: 29266677 DOI: 10.1111/obr.12657] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 10/30/2017] [Accepted: 11/14/2017] [Indexed: 11/29/2022]
Abstract
Curbing the obesity epidemic is likely to require a suite of interventions targeting the obesogenic environment as well as individual behaviour. Evidence suggests that the effectiveness of behaviour modification programmes can be enhanced by financial incentives that immediately reward weight loss behaviour. This systematic review investigated the effectiveness of incentives with a focus on assessing the relative effectiveness of incentives that target different behaviours as well as factors of importance when implementing these programmes in real-world settings (health insurer settings). A narrative review of the academic and grey literature including a variety of study designs was undertaken. Twenty studies met inclusion criteria and were assessed using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies. Results suggest that incentivizing weight loss is effective in the short term while the incentives are in place. There are various incentive designs, and although the relative effectiveness of each of these on weight loss is not clear, it appears that positive incentives increase the uptake into programmes and may reduce dropouts. As with other weight loss initiatives, there is a need to explore ways to maintain weight loss in the longer term - incentives for weight maintenance could play a role.
Collapse
Affiliation(s)
- J Ananthapavan
- Deakin University, Geelong, Australia, Deakin Health Economics, Centre for Population Health Research.,Deakin University, Geelong, Australia, Global Obesity Centre, Centre for Population Health Research
| | - A Peterson
- Deakin University, Geelong, Australia, Deakin Health Economics, Centre for Population Health Research
| | - G Sacks
- Deakin University, Geelong, Australia, Global Obesity Centre, Centre for Population Health Research
| |
Collapse
|
16
|
Krop I, Abramson V, Colleoni M, Holmes FA, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly CM, Uppal H, Tudor IC, Peterson A, Winer E, Yardley DA. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- I Krop
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - V Abramson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Colleoni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - FA Holmes
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Estevez
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Hart
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Awada
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - C Zamagni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - P Morris
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Schwartzberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - S Chan
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - D Wheatley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Guculp
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Biganzoli
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - J Steinberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Gianni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Trudeau
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - CM Kelly
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - H Uppal
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - IC Tudor
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Peterson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - DA Yardley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| |
Collapse
|
17
|
Kim R, Peterson A, Isherwood A, Uppal H, Barlev A. Abstract P5-08-28: Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is the most common cancer and second leading cause of cancer death among women in the United States (US).1 Inherited mutations in germline breast cancer susceptibility gene 1 and 2 (gBRCAm) are associated with increased risk of developing cancers, including breast cancer.2 No published reports of gBRCAm incidence within an unselected US breast cancer population are available based on a comprehensive literature review (CLR). The main objective of this analysis is to estimate the incidence of gBRCAm breast cancer in the US.
Methods: For this analysis the Surveillance, Epidemiology, and End Results (SEER) Program 18 registries captured incidence of breast cancer by stage, age and gender.3 The size of the US population was based on United Nation's population projections and standardized to the 2010 population.4 Age-specific gBRCAm distribution and gBRCAm-specific hormonal subtype for estrogen-receptor and progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2) estimates were determined from a CLR.5-8 Tumor cells negative for ER/PR and HER2 are referred to as triple-negative breast cancer (TNBC).
Results: In 2016, it is projected that approximately 250,000 individuals will be diagnosed with invasive breast cancer (all genders). Median age range of the population with invasive breast cancer is 65-69 years and 99% are females. Majority (72%) of female invasive breast cancer cases are ER/PR+ whereas 11% of cases are TNBC. Corroborating with current publications, gBRCAm is estimated at 5% for individuals less than 50 years old and 1% among all ages. Median age range of the gBRCAm cohort is 40-44 years. After applying currently available gBRCAm specific literature parameters, the majority (55%) of gBRCAm diagnoses are TNBC.
Conclusion: In the US, patients with gBRCAm represent a small proportion (1%) of all breast cancer tissues evaluated. Majority of gBRCAm patients are diagnosed with TNBC (55%) and are younger (median age range 40-44 years) than overall breast cancer population. Age differences noticed in gBRCAm may have been due to disparity in genetic screening practices among breast cancer population in the US rather than a reflection of gBRCAm expressions. These estimates of gBRCAm incidence are driven by limited reports on an unselected population of breast cancer gBRCAm cohort; therefore sensitivity analysis is required to assess the robustness of these estimates.
1. American Cancer Society. Facts and Figures 2016.
2. Miki Y et al. Science. 1994;266:66-71.
3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2013), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
4. United Nations Population Division. World Population Prospects, the 2015 Revision. http://esa.un.org/unpd/wpp/.
5. van den Broek et al. Eur J Hum Genet. 2015;23:588-95.
6.Turkovic L et al. BMC Cancer. 2010;10:466.
7. Atchley DP et al. J Clin Oncol. 2008;26:4282-4321.
8. Spurdle AB et al. Breast Cancer Res. 2014;16:3419.
Citation Format: Kim R, Peterson A, Isherwood A, Uppal H, Barlev A. Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-28.
Collapse
Affiliation(s)
- R Kim
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - A Peterson
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - A Isherwood
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - H Uppal
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - A Barlev
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| |
Collapse
|
18
|
Litton J, Ettl J, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Yerushalmi R, Woodward N, Goncalves A, Moreno F, Roche H, Im YH, Martin M, Bhattacharya S, Peterson A, Hannah A, Eiermann W, Blum J. Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cancer cells with deleterious mutations in breast cancer susceptibility genes 1 and 2 (BRCA1/2) are deficient in the DNA double-strand break repair mechanism, rendering them highly dependent on the single-strand break repair pathway, regulated by poly(ADP-ribose) polymerase (PARP). Inhibition of PARP results in synthetic lethality in cells with a BRCA1/2 mutation because of accumulation of irreparable DNA damage; PARP inhibitors have the potential to be selectively toxic for BRCA-mutated cells. In addition to catalytic inhibition, it has been shown that some PARP inhibitors induce PARP trapping at sites of DNA damage. The capacity to trap PARP-DNA complexes varies widely across different PARP inhibitors and is not correlated with PARP catalytic inhibition. Preclinical models have shown trapping PARP on DNA is more potent at inducing cancer cell death than enzymatic inhibition of PARP alone. Talazoparib is a dual-mechanism PARP inhibitor that both inhibits the PARP enzyme and effectively traps PARP on DNA, preventing DNA damage repair and resulting in cell death in BRCA1/2-mutated cells. In preclinical studies, talazoparib at nanomolar concentrations showed the highest efficiency at trapping PARP-DNA complexes relative to other PARP inhibitors. In a previous phase 1/2 clinical study, talazoparib as monotherapy (1 mg once daily) resulted in a 50% response rate and an 86% clinical benefit rate at 24 weeks in 14 patients with a germline BRCA1/2 mutation and advanced breast cancer (aBC).
Methods: This open-label, randomized, 2-arm, international phase 3 trial (EMBRACA)
compares the efficacy and safety of talazoparib with protocol-specific physician's choice (capecitabine, eribulin, gemcitabine or vinorelbine) in patients with aBC. The primary objective is progression-free survival by central imaging. Secondary objectives are objective response rate, overall survival, safety and pharmacokinetics of talazoparib. Exploratory objectives include health-related quality of life measurements and biomarker research in blood and tumor samples that may permit characterization of mechanisms involved in tumor sensitivity and resistance to talazoparib. Key patient eligibility criteria include aged ≥18 years with histologically/cytologically confirmed breast cancer; locally advanced and/or metastatic disease appropriate for systemic single-agent cytotoxic chemotherapy; deleterious or pathogenic germline BRCA1/2 mutations by central laboratory; ≤3 prior cytotoxic chemotherapy regimens for advanced disease (prior platinum is allowed provided patients did not relapse within 6 months in the adjuvant setting or did not progress on platinum therapy); prior treatment with a taxane and/or anthracycline unless medically contraindicated; and ECOG performance status ≤2. Patients (N=429) will be randomized 2:1 to receive either talazoparib capsules (1 mg/day, 21-day cycles) or physician's choice treatment. This trial is currently enrolling patients from the USA, Europe, Israel, Ukraine, Russia, Korea, Australia, Taiwan and Brazil (NCT01945775).
This study is funded by Medivation, Inc.
Citation Format: Litton J, Ettl J, Hurvitz SA, Mina LA, Rugo HS, Lee K-H, Yerushalmi R, Woodward N, Goncalves A, Moreno F, Roche H, Im Y-H, Martin M, Bhattacharya S, Peterson A, Hannah A, Eiermann W, Blum J. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-13.
Collapse
Affiliation(s)
- J Litton
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - J Ettl
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - SA Hurvitz
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - LA Mina
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - HS Rugo
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - K-H Lee
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - R Yerushalmi
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - N Woodward
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Goncalves
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - F Moreno
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - H Roche
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - Y-H Im
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - M Martin
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - S Bhattacharya
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Peterson
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Hannah
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - W Eiermann
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - J Blum
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| |
Collapse
|
19
|
Abstract
Abstract
Background: BRCA1 and BRCA2 functions are essential for the DNA double-strand break repair process in living cells with DNA damages. Therefore, germline pathogenic mutations in BRCA1/2 increases the risk of developing cancer.1, 2Poly(ADP-ribose) polymerase (PARP) enzymes are proteins responsible for DNA single-strand break repair. Persistent inhibition of PARP-dependent DNA repair in BRCA-deficient breast cancer cells leads to increased DNA damages resulting in cancer cell death. Talazoparib is a novel and potent, orally bioavailable, small molecule PARP inhibitor. Talazoparib's dual mechanism of action inhibits PARP enzyme activity and effectively traps PARP on DNA, preventing DNA repair, resulting in cell death in BRCA1/2-mutated cells.3 In tissue culture studies, talazoparib is more potent at trapping PARP on DNA to induce cancer cell death compared to other PARP inhibitors.4 Previous studies have demonstrated talazoparib inhibited growth in tumors harboring BRCA1/2 gene mutations. In the MX-1 breast cancer model with BRCA1-deficiency, talazoparib inhibited cell growth in vitro and induced regression in solid mouse xenografts.5 Here, we demonstrate antitumor effects of talazoparib monotherapy in a panel of breast cancer cells and patient-derived breast cancer models with pathologic BRCA1/2 mutations.
Method: A panel of human breast cancer cell lines was treated with talazoparib to determine its cytotoxic effects. BRCA1/2 mutations status was correlated to talazoparib cytotoxic effects. At the molecular level, BRCA1/2-mutant and wild type breast cancer cell lines were treated with dose-escalating talazoparib to also assess the relationship between PARP-DNA trapping complex formation and treatment response. Patient-derived breast cancer xenograft models were used to assess talazoparib monotherapy on tumorigenesis. Immunohistochemistry assays were performed to determine Ki-67, gH2AX and caspase 3 marker expression following talazoparib treatment.
Results: Cytotoxicity was observed in 50% (7/14) cell lines at IC50 values that are achieved in the clinic. BRCA1/2 alterations were detected in 21.4% (3/14) of cell lines sensitive to talazoparib treatment. In 14 patient-derived breast cancer xenograft models selected for this study, 57.1% (8/14) responded to talazoparib monotherapy. Of these, 35.7% had mutations in the BRCA1 (28.6%) and BRCA2 (7.1%) genes. Stable disease was observed in 14.2% (2/14). One stable model had BRCA1 mutations. Tumor regression was observed in 42.8% (6/14) of the models treated with talazoparib monotherapy. Importantly, 66.7% (4/6) of patient-derived breast cancer models that regressed on talazoparib monotherapy had mutations in BRCA1/2 genes.
Conclusions: Cytotoxicity was observed with talazoparib monotherapy in breast cancer cell lines and in patient-derived xenograft tumor models harboring BRCA1 or BRCA2 mutations. Our data demonstrate therapeutic potential of talazoparib monotherapy in breast cancer associated with pathologic BRCA1/2 mutations.
1.Couch FJ et al. J Clin Oncol. 2015;33:304-11.
2. Petrucelli N et al. Genet Med. 2010;12:245-59.
3. Wang B et al. J Med Chem. 2016;59:335-57.
4. Murai J et al. Mol Cancer Ther. 2014;13:433-43.
5. Shen Y et al. Clin Cancer Res. 2013;19:5003-15.
Citation Format: Phan VT, Protter AA, Peterson A, Uppal H. Talazoparib antitumor effects in BRCA-deficient breast cancer models [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-06-01.
Collapse
Affiliation(s)
- VT Phan
- Medivation, Inc., San Francisco, CA
| | | | | | - H Uppal
- Medivation, Inc., San Francisco, CA
| |
Collapse
|
20
|
Krop I, Cortes J, Miller K, Huizing MT, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton VE, Peterson A, Wardley A. Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-08] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Androgen receptor (AR) expression has been observed in up to 77% of human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC).References:1 Enzalutamide (ENZA) is a potent AR inhibitor approved for patients (pts) with metastatic castration-resistant prostate cancer. In vitro, ENZA enhances antitumor activity of trastuzumab in HER2+ AR+ cell lines and inhibits proliferation in trastuzumab-resistant HER2+ cell lines.2
Methods:Pts with metastatic or locally advanced BC that was HER2+ AR+ by local or central laboratory assessment were enrolled in a single-arm, Simon 2-stage phase 2 study (NCT02091960). Key eligibility criteria included availability of a tissue sample, presence of measurable or evaluable disease per RECIST v1.1, progression on prior trastuzumab and ≥1 prior line of anti-HER2 therapy as the most recent regimen. Brain metastases and history of seizure were exclusionary. Evaluable pts were those with centrally confirmed nuclear AR expression≥10% by immunohistochemistry who received ≥1 dose of ENZA and had ≥1 postbaseline tumor assessment. Pts received ENZA 160 mg daily and trastuzumab 6 mg/kg every 21 days until disease progression. The primary objective was clinical benefit rate at 24 weeks (CBR24), defined as complete or partial response (CR or PR) or stable disease (SD) for ≥24 weeks in evaluable pts. Additional endpoints included safety and progression-free survival (PFS). CBR24 in ≥3 of 21 evaluable pts was required to continue to stage 2 and enrollment of up to 66 evaluable pts total. This design yields a 1-sided type 1 error of 5% and 90% power when the true response is 25%.
Results:Here we present results from stage 1 (data cutoff: Mar 23, 2016), with 22 evaluable pts enrolled (pts 21 and 22 enrolled simultaneously); 18 had received ≥4 prior lines of therapy. Median duration of ENZA exposure was 144 days (range, 22-495), mean number of complete trastuzumab infusions was 6.5. CBR24 was 27.3% (95% confidence interval [CI], 10.7-50.2); 2 confirmed PR and 4 SD ≥24 weeks. Median PFS was 108 days (95% CI, 56-144). All pts experienced ≥1 adverse event (AE) any grade; 5 pts experienced AEs grade ≥3. ENZA-related AEs were reported in 16 pts (72.7%), the most common (in ≥10% of pts) were fatigue (22.7%), nausea (18.2%), diarrhea (13.6%) and arthralgia (13.6%). Serious AEs were reported in 6 pts (27.3%; 2 each of infection and back pain, 1 each of abdominal pain, nausea, vomiting, pyrexia, urinary retention and pulmonary edema). Two pts discontinued due to drug-related AEs: 1 related to both drugs, 1 related to trastuzumab. One on-study death from pulmonary edema was reported, which was not considered related to either drug.
Conclusion:Stage 1 met its primary objective. No new safety signals were identified, and the safety profile in this study was similar to that in men with prostate cancer and women with other BC subtypes treated with ENZA. These results are encouraging for a heavily pretreated population with advanced HER2+ AR+ BC. Enrollment in stage 2 continues with the combination of ENZA and trastuzumab.
1. Micello D et al. Virchows Arch. 2010;457:467-476.
2. Richer J. Presented at AACR Advances in Breast Cancer, San Diego, CA, 2013.
Citation Format: Krop I, Cortes J, Miller K, Huizing MT, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton VE, Peterson A, Wardley A. A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-08.
Collapse
Affiliation(s)
- I Krop
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Cortes
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - K Miller
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - MT Huizing
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - L Provencher
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - L Gianni
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - S Chan
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - M Trudeau
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Steinberg
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Sugg
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - M Liosatos
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - VE Paton
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - A Peterson
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - A Wardley
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| |
Collapse
|
21
|
Peterson A, Brown A, Savage A, Dempsey A. Factors associated with bleeding evaluation and early discontinuation among etonogestrel contraceptive implant users. Contraception 2016. [DOI: 10.1016/j.contraception.2016.07.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Abstract
The sudden emergence and worldwide adoption of CRISPR gene-editing technology confronts humanity with unprecedented opportunities and choices. CRISPR's transformative impact on our future understanding of biology, along with its potential to unleash control over the most fundamental of biological processes, is predictable by already achieved applications. Although its origin, composition, and function were revealed only recently, close to 3000 CRISPR-based publications have appeared including insightful and diversely focused reviews referenced here. Adding further to scientific and public awareness, a recent symposium addressed the ethical implications of interfacing CRISPR technology and human biology. However, the magnitude of CRISPR's rapidly emerging power mandates its broadest assessment. Only with the participation of a diverse and informed community can the most effective and humanity-positive CRISPR applications be defined. This brief review is aimed at those with little previous exposure to the CRISPR revolution. The molecules that constitute CRISPR's core components and their functional organization are described along with how the mechanism has been harnessed to edit genome structure and modulate gene function. Additionally, a glimpse into CRISPR's potential to unleash genetic changes with far-reaching consequences is presented.
Collapse
Affiliation(s)
- A Peterson
- Laboratory of Developmental Biology, Departments of Oncology, Human Genetics, Neurology & Neurosurgery, McGill University, Montreal, QC, Canada
| |
Collapse
|
23
|
Mendez M, Cone E, Lavien G, Zaid U, Peterson A, Lentz A. 047 Recovery of Glans Sensation Following Combined Dorsal and Ventral Onlay with a Glans Splitting Technique for Strictures of the Fossa Navicularis. J Sex Med 2016. [DOI: 10.1016/j.jsxm.2016.02.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Peterson A, Hennemeyer C. Denver peritoneo-venous shunt (DPVS): an essential tool in the management of malignant ascites. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
25
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Bairathi V, Banerjee A, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Bouchet J, Brandin AV, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Cervantes MC, Chakaberia I, Chaloupka P, Chang Z, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Das S, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, di Ruzza B, Didenko L, Dilks C, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Eppley G, Esha R, Evdokimov O, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Z, Filip P, Fisyak Y, Flores CE, Fulek L, Gagliardi CA, Garand D, Geurts F, Gibson A, Girard M, Greiner L, Grosnick D, Gunarathne DS, Guo Y, Gupta S, Gupta A, Guryn W, Hamad A, Hamed A, Haque R, Harris JW, He L, Heppelmann S, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang X, Huang B, Huang HZ, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Jiang K, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Khan ZH, Kikoła DP, Kisel I, Kisiel A, Kochenda L, Koetke DD, Kollegger T, Kosarzewski LK, Kraishan AF, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Li ZM, Li W, Li X, Li X, Li C, Li Y, Lisa MA, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Ma YG, Ma GL, Ma L, Ma R, Magdy N, Majka R, Manion A, Margetis S, Markert C, Masui H, Matis HS, McDonald D, Meehan K, Minaev NG, Mioduszewski S, Mishra D, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nigmatkulov G, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Okorokov V, Olvitt D, Page BS, Pak R, Pan YX, Pandit Y, Panebratsev Y, Pawlik B, Pei H, Perkins C, Peterson A, Pile P, Planinic M, Pluta J, Poljak N, Poniatowska K, Porter J, Posik M, Poskanzer AM, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Roy A, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandweiss J, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Sharma MK, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Sikora R, Simko M, Singha S, Skoby MJ, Smirnov D, Smirnov N, Song L, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stepanov M, Stock R, Strikhanov M, Stringfellow B, Sumbera M, Summa B, Sun X, Sun XM, Sun Y, Sun Z, Surrow B, Svirida N, Szelezniak MA, Tang AH, Tang Z, Tarnowsky T, Tawfik A, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Trzeciak BA, Tsai OD, Ullrich T, Underwood DG, Upsal I, Van Buren G, van Nieuwenhuizen G, Vandenbroucke M, Varma R, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Voloshin SA, Vossen A, Wang Y, Wang G, Wang JS, Wang H, Wang Y, Wang F, Webb JC, Webb G, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Wu Y, Xiao ZG, Xie W, Xin K, Xu N, Xu Z, Xu QH, Xu YF, Xu H, Yang Q, Yang Y, Yang Y, Yang S, Yang C, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang Z, Zhang Y, Zhang JB, Zhang J, Zhang S, Zhang J, Zhang XP, Zhao J, Zhong C, Zhou L, Zhu X, Zoulkarneeva Y, Zyzak M. Centrality and Transverse Momentum Dependence of Elliptic Flow of Multistrange Hadrons and ϕ Meson in Au+Au Collisions at √[sNN]=200 GeV. Phys Rev Lett 2016; 116:062301. [PMID: 26918982 DOI: 10.1103/physrevlett.116.062301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Indexed: 06/05/2023]
Abstract
We present high precision measurements of elliptic flow near midrapidity (|y|<1.0) for multistrange hadrons and ϕ meson as a function of centrality and transverse momentum in Au+Au collisions at center of mass energy √[sNN]=200 GeV. We observe that the transverse momentum dependence of ϕ and Ω v2 is similar to that of π and p, respectively, which may indicate that the heavier strange quark flows as strongly as the lighter up and down quarks. This observation constitutes a clear piece of evidence for the development of partonic collectivity in heavy-ion collisions at the top RHIC energy. Number of constituent quark scaling is found to hold within statistical uncertainty for both 0%-30% and 30%-80% collision centrality. There is an indication of the breakdown of previously observed mass ordering between ϕ and proton v2 at low transverse momentum in the 0%-30% centrality range, possibly indicating late hadronic interactions affecting the proton v2.
Collapse
Affiliation(s)
- L Adamczyk
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - J K Adkins
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - D Arkhipkin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E C Aschenauer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Averichev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - V Bairathi
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - A Banerjee
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - R Bellwied
- University of Houston, Houston, Texas 77204, USA
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - A K Bhati
- Panjab University, Chandigarh 160014, India
| | - P Bhattarai
- University of Texas, Austin, Texas 78712, USA
| | - J Bielcik
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - J Bielcikova
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - L C Bland
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - J Bouchet
- Kent State University, Kent, Ohio 44242, USA
| | - A V Brandin
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - I Bunzarov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - H Caines
- Yale University, New Haven, Connecticut 06520, USA
| | | | - J M Campbell
- Ohio State University, Columbus, Ohio 43210, USA
| | - D Cebra
- University of California, Davis, California 95616, USA
| | - M C Cervantes
- Texas A&M University, College Station, Texas 77843, USA
| | - I Chakaberia
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Chaloupka
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - Z Chang
- Texas A&M University, College Station, Texas 77843, USA
| | | | - J H Chen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Chen
- Institute of Modern Physics, Lanzhou 730000, China
| | - J Cheng
- Tsinghua University, Beijing 100084, China
| | - M Cherney
- Creighton University, Omaha, Nebraska 68178, USA
| | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Contin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H J Crawford
- University of California, Berkeley, California 94720, USA
| | - S Das
- Institute of Physics, Bhubaneswar 751005, India
| | - L C De Silva
- Creighton University, Omaha, Nebraska 68178, USA
| | - R R Debbe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Deng
- Shandong University, Jinan, Shandong 250100, China
| | | | - B di Ruzza
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Dilks
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J E Draper
- University of California, Davis, California 95616, USA
| | - C M Du
- Institute of Modern Physics, Lanzhou 730000, China
| | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L G Efimov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Engelage
- University of California, Berkeley, California 94720, USA
| | - G Eppley
- Rice University, Houston, Texas 77251, USA
| | - R Esha
- University of California, Los Angeles, California 90095, USA
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - O Eyser
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - S Fazio
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Federic
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - J Fedorisin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Z Feng
- Central China Normal University (HZNU), Wuhan 430079, China
| | - P Filip
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C E Flores
- University of California, Davis, California 95616, USA
| | - L Fulek
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - C A Gagliardi
- Texas A&M University, College Station, Texas 77843, USA
| | - D Garand
- Purdue University, West Lafayette, Indiana 47907, USA
| | - F Geurts
- Rice University, Houston, Texas 77251, USA
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - M Girard
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Greiner
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - D S Gunarathne
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - Y Guo
- University of Science and Technology of China, Hefei 230026, China
| | - S Gupta
- University of Jammu, Jammu 180001, India
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - W Guryn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Hamad
- Kent State University, Kent, Ohio 44242, USA
| | - A Hamed
- Texas A&M University, College Station, Texas 77843, USA
| | - R Haque
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - J W Harris
- Yale University, New Haven, Connecticut 06520, USA
| | - L He
- Purdue University, West Lafayette, Indiana 47907, USA
| | - S Heppelmann
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Heppelmann
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Hirsch
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - D J Hofman
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - S Horvat
- Yale University, New Haven, Connecticut 06520, USA
| | - X Huang
- Tsinghua University, Beijing 100084, China
| | - B Huang
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - H Z Huang
- University of California, Los Angeles, California 90095, USA
| | - P Huck
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T J Humanic
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Igo
- University of California, Los Angeles, California 90095, USA
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - H Jang
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - K Jiang
- University of Science and Technology of China, Hefei 230026, China
| | - E G Judd
- University of California, Berkeley, California 94720, USA
| | - S Kabana
- Kent State University, Kent, Ohio 44242, USA
| | - D Kalinkin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - K Kang
- Tsinghua University, Beijing 100084, China
| | - K Kauder
- Wayne State University, Detroit, Michigan 48201, USA
| | - H W Ke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Keane
- Kent State University, Kent, Ohio 44242, USA
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Z H Khan
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - D P Kikoła
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - I Kisel
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - A Kisiel
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Kochenda
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D D Koetke
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - T Kollegger
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | | | - A F Kraishan
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - P Kravtsov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - K Krueger
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Kulakov
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - L Kumar
- Panjab University, Chandigarh 160014, India
| | - R A Kycia
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - M A C Lamont
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K D Landry
- University of California, Los Angeles, California 90095, USA
| | - J Lauret
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z M Li
- Central China Normal University (HZNU), Wuhan 430079, China
| | - W Li
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Li
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Li
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C Li
- University of Science and Technology of China, Hefei 230026, China
| | - Y Li
- Tsinghua University, Beijing 100084, China
| | - M A Lisa
- Ohio State University, Columbus, Ohio 43210, USA
| | - F Liu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W J Llope
- Wayne State University, Detroit, Michigan 48201, USA
| | - M Lomnitz
- Kent State University, Kent, Ohio 44242, USA
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Luo
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y G Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - G L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - R Ma
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Magdy
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - R Majka
- Yale University, New Haven, Connecticut 06520, USA
| | - A Manion
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Margetis
- Kent State University, Kent, Ohio 44242, USA
| | - C Markert
- University of Texas, Austin, Texas 78712, USA
| | - H Masui
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D McDonald
- University of Houston, Houston, Texas 77204, USA
| | - K Meehan
- University of California, Davis, California 95616, USA
| | - N G Minaev
- Institute of High Energy Physics, Protvino 142281, Russia
| | | | - D Mishra
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - B Mohanty
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - M M Mondal
- Texas A&M University, College Station, Texas 77843, USA
| | - D A Morozov
- Institute of High Energy Physics, Protvino 142281, Russia
| | - M K Mustafa
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B K Nandi
- Indian Institute of Technology, Mumbai 400076, India
| | - Md Nasim
- University of California, Los Angeles, California 90095, USA
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - G Nigmatkulov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - L V Nogach
- Institute of High Energy Physics, Protvino 142281, Russia
| | - S Y Noh
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - J Novak
- Michigan State University, East Lansing, Michigan 48824, USA
| | - S B Nurushev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Oh
- Pusan National University, Pusan 609735, Republic of Korea
| | - V Okorokov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D Olvitt
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - B S Page
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Pak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y X Pan
- University of California, Los Angeles, California 90095, USA
| | - Y Pandit
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - Y Panebratsev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - B Pawlik
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - H Pei
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Perkins
- University of California, Berkeley, California 94720, USA
| | - A Peterson
- Ohio State University, Columbus, Ohio 43210, USA
| | - P Pile
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Planinic
- University of Zagreb, Zagreb HR-10002, Croatia
| | - J Pluta
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - N Poljak
- University of Zagreb, Zagreb HR-10002, Croatia
| | - K Poniatowska
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Posik
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A M Poskanzer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Putschke
- Wayne State University, Detroit, Michigan 48201, USA
| | - H Qiu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Quintero
- Kent State University, Kent, Ohio 44242, USA
| | - S Ramachandran
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - R Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - S Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R L Ray
- University of Texas, Austin, Texas 78712, USA
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | - J L Romero
- University of California, Davis, California 95616, USA
| | - A Roy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Rusnak
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - O Rusnakova
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - N R Sahoo
- Texas A&M University, College Station, Texas 77843, USA
| | - P K Sahu
- Institute of Physics, Bhubaneswar 751005, India
| | - I Sakrejda
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Salur
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Sandweiss
- Yale University, New Haven, Connecticut 06520, USA
| | - A Sarkar
- Indian Institute of Technology, Mumbai 400076, India
| | - J Schambach
- University of Texas, Austin, Texas 78712, USA
| | | | - A M Schmah
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Schmitz
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178, USA
| | - P Seyboth
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - N Shah
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - M Shao
- University of Science and Technology of China, Hefei 230026, China
| | - B Sharma
- Panjab University, Chandigarh 160014, India
| | - M K Sharma
- University of Jammu, Jammu 180001, India
| | - W Q Shen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S S Shi
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Q Y Shou
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E P Sichtermann
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Sikora
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - M Simko
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - S Singha
- Kent State University, Kent, Ohio 44242, USA
| | - M J Skoby
- Indiana University, Bloomington, Indiana 47408, USA
| | - D Smirnov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Smirnov
- Yale University, New Haven, Connecticut 06520, USA
| | - L Song
- University of Houston, Houston, Texas 77204, USA
| | - P Sorensen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H M Spinka
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - M Stepanov
- Purdue University, West Lafayette, Indiana 47907, USA
| | - R Stock
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - M Strikhanov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | | | - M Sumbera
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - B Summa
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - X M Sun
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Sun
- University of Science and Technology of China, Hefei 230026, China
| | - Z Sun
- Institute of Modern Physics, Lanzhou 730000, China
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - M A Szelezniak
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Tang
- University of Science and Technology of China, Hefei 230026, China
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824, USA
| | - A Tawfik
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Timmins
- University of Houston, Houston, Texas 77204, USA
| | - D Tlusty
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S Trentalange
- University of California, Los Angeles, California 90095, USA
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843, USA
| | - P Tribedy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | | | - B A Trzeciak
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - O D Tsai
- University of California, Los Angeles, California 90095, USA
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Upsal
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | - R Varma
- Indian Institute of Technology, Mumbai 400076, India
| | - A N Vasiliev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - R Vertesi
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y P Viyogi
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S A Voloshin
- Wayne State University, Detroit, Michigan 48201, USA
| | - A Vossen
- Indiana University, Bloomington, Indiana 47408, USA
| | - Y Wang
- Tsinghua University, Beijing 100084, China
| | - G Wang
- University of California, Los Angeles, California 90095, USA
| | - J S Wang
- Institute of Modern Physics, Lanzhou 730000, China
| | - H Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y Wang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - F Wang
- Purdue University, West Lafayette, Indiana 47907, USA
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Wen
- University of California, Los Angeles, California 90095, USA
| | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824, USA
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408, USA
| | - R Witt
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - Y F Wu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Wu
- Kent State University, Kent, Ohio 44242, USA
| | - Z G Xiao
- Tsinghua University, Beijing 100084, China
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Xin
- Rice University, Houston, Texas 77251, USA
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Q H Xu
- Shandong University, Jinan, Shandong 250100, China
| | - Y F Xu
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - H Xu
- Institute of Modern Physics, Lanzhou 730000, China
| | - Q Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Y Yang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Yang
- Institute of Modern Physics, Lanzhou 730000, China
| | - S Yang
- University of Science and Technology of China, Hefei 230026, China
| | - C Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - P Yepes
- Rice University, Houston, Texas 77251, USA
| | - L Yi
- Yale University, New Haven, Connecticut 06520, USA
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I-K Yoo
- Pusan National University, Pusan 609735, Republic of Korea
| | - N Yu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - H Zbroszczyk
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - W Zha
- University of Science and Technology of China, Hefei 230026, China
| | - Z Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y Zhang
- University of Science and Technology of China, Hefei 230026, China
| | - J B Zhang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - J Zhang
- Shandong University, Jinan, Shandong 250100, China
| | - S Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - J Zhang
- Institute of Modern Physics, Lanzhou 730000, China
| | - X P Zhang
- Tsinghua University, Beijing 100084, China
| | - J Zhao
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Zhong
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Zhou
- University of Science and Technology of China, Hefei 230026, China
| | - X Zhu
- Tsinghua University, Beijing 100084, China
| | - Y Zoulkarneeva
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| |
Collapse
|
26
|
Li L, Peterson A, Soos T, Arendt C, Jones C. Redirection of Human CD4+ T Cell Responses with the Toll-like Receptor 4 (TLR4) Agonist Glucopyranosyl Lipid a (GLA). J Allergy Clin Immunol 2016. [DOI: 10.1016/j.jaci.2015.12.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Alford J, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Banerjee A, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Bouchet J, Brandin AV, Bunzarov I, Burton TP, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Cervantes MC, Chakaberia I, Chaloupka P, Chang Z, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Das S, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, di Ruzza B, Didenko L, Dilks C, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Eppley G, Esha R, Evdokimov O, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Z, Filip P, Fisyak Y, Flores CE, Fulek L, Gagliardi CA, Garand D, Geurts F, Gibson A, Girard M, Greiner L, Grosnick D, Gunarathne DS, Guo Y, Gupta S, Gupta A, Guryn W, Hamad A, Hamed A, Haque R, Harris JW, He L, Heppelmann S, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang B, Huang X, Huang HZ, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Jiang K, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Khan ZH, Kikola DP, Kisel I, Kisiel A, Kochenda L, Koetke DD, Kollegger T, Kosarzewski LK, Kraishan AF, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Li X, Li C, Li W, Li ZM, Li Y, Li X, Lisa MA, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Ma YG, Ma GL, Ma L, Ma R, Magdy N, Majka R, Manion A, Margetis S, Markert C, Masui H, Matis HS, McDonald D, Meehan K, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Morozov D, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nigmatkulov G, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Okorokov V, Olvitt D, Page BS, Pak R, Pan YX, Pandit Y, Panebratsev Y, Pawlik B, Pei H, Perkins C, Peterson A, Pile P, Planinic M, Pluta J, Poljak N, Poniatowska K, Porter J, Posik M, Poskanzer AM, Pruthi NK, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Roy A, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandweiss J, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma MK, Sharma B, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Sikora R, Simko M, Skoby MJ, Smirnov D, Smirnov N, Song L, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stepanov M, Stock R, Strikhanov M, Stringfellow B, Sumbera M, Summa B, Sun X, Sun Z, Sun XM, Sun Y, Surrow B, Svirida N, Szelezniak MA, Tang AH, Tang Z, Tarnowsky T, Tawfik AN, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Trzeciak BA, Tsai OD, Ullrich T, Underwood DG, Upsal I, Van Buren G, van Nieuwenhuizen G, Vandenbroucke M, Varma R, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Voloshin SA, Vossen A, Wang G, Wang Y, Wang F, Wang Y, Wang H, Wang JS, Webb JC, Webb G, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Xiao ZG, Xie W, Xin K, Xu QH, Xu Z, Xu H, Xu N, Xu YF, Yang Q, Yang Y, Yang S, Yang Y, Yang C, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang XP, Zhang J, Zhang Y, Zhang J, Zhang JB, Zhang S, Zhang Z, Zhao J, Zhong C, Zhou L, Zhu X, Zoulkarneeva Y, Zyzak M. Observation of Transverse Spin-Dependent Azimuthal Correlations of Charged Pion Pairs in p^{↑}+p at sqrt[s]=200 GeV. Phys Rev Lett 2015; 115:242501. [PMID: 26705627 DOI: 10.1103/physrevlett.115.242501] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Indexed: 06/05/2023]
Abstract
We report the observation of transverse polarization-dependent azimuthal correlations in charged pion pair production with the STAR experiment in p^{↑}+p collisions at RHIC. These correlations directly probe quark transversity distributions. We measure signals in excess of 5 standard deviations at high transverse momenta, at high pseudorapidities η>0.5, and for pair masses around the mass of the ρ meson. This is the first direct transversity measurement in p+p collisions.
Collapse
Affiliation(s)
- L Adamczyk
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - J K Adkins
- University of Kentucky, Lexington, Kentucky, 40506-0055, USA
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - J Alford
- Kent State University, Kent, Ohio 44242, USA
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - D Arkhipkin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E C Aschenauer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Averichev
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - A Banerjee
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - R Bellwied
- University of Houston, Houston, Texas 77204, USA
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - A K Bhati
- Panjab University, Chandigarh 160014, India
| | - P Bhattarai
- University of Texas, Austin, Texas 78712, USA
| | - J Bielcik
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - J Bielcikova
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - L C Bland
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - J Bouchet
- Kent State University, Kent, Ohio 44242, USA
| | - A V Brandin
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - I Bunzarov
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - T P Burton
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | - H Caines
- Yale University, New Haven, Connecticut 06520, USA
| | | | - J M Campbell
- Ohio State University, Columbus, Ohio 43210, USA
| | - D Cebra
- University of California, Davis, California 95616, USA
| | - M C Cervantes
- Texas A&M University, College Station, Texas 77843, USA
| | - I Chakaberia
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Chaloupka
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - Z Chang
- Texas A&M University, College Station, Texas 77843, USA
| | | | - J H Chen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Chen
- Institute of Modern Physics, Lanzhou 730000, China
| | - J Cheng
- Tsinghua University, Beijing 100084, China
| | - M Cherney
- Creighton University, Omaha, Nebraska 68178, USA
| | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Contin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H J Crawford
- University of California, Berkeley, California 94720, USA
| | - S Das
- Institute of Physics, Bhubaneswar 751005, India
| | - L C De Silva
- Creighton University, Omaha, Nebraska 68178, USA
| | - R R Debbe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - J Deng
- Shandong University, Jinan, Shandong 250100, China
| | | | - B di Ruzza
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Dilks
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J E Draper
- University of California, Davis, California 95616, USA
| | - C M Du
- Institute of Modern Physics, Lanzhou 730000, China
| | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L G Efimov
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - J Engelage
- University of California, Berkeley, California 94720, USA
| | - G Eppley
- Rice University, Houston, Texas 77251, USA
| | - R Esha
- University of California, Los Angeles, California 90095, USA
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - O Eyser
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky, 40506-0055, USA
| | - S Fazio
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Federic
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - J Fedorisin
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - Z Feng
- Central China Normal University (HZNU), Wuhan 430079, China
| | - P Filip
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C E Flores
- University of California, Davis, California 95616, USA
| | - L Fulek
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - C A Gagliardi
- Texas A&M University, College Station, Texas 77843, USA
| | - D Garand
- Purdue University, West Lafayette, Indiana 47907, USA
| | - F Geurts
- Rice University, Houston, Texas 77251, USA
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - M Girard
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Greiner
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - D S Gunarathne
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - Y Guo
- University of Science and Technology of China, Hefei 230026, China
| | - S Gupta
- University of Jammu, Jammu 180001, India
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - W Guryn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Hamad
- Kent State University, Kent, Ohio 44242, USA
| | - A Hamed
- Texas A&M University, College Station, Texas 77843, USA
| | - R Haque
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - J W Harris
- Yale University, New Haven, Connecticut 06520, USA
| | - L He
- Purdue University, West Lafayette, Indiana 47907, USA
| | - S Heppelmann
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - S Heppelmann
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Hirsch
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - D J Hofman
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - S Horvat
- Yale University, New Haven, Connecticut 06520, USA
| | - B Huang
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - X Huang
- Tsinghua University, Beijing 100084, China
| | - H Z Huang
- University of California, Los Angeles, California 90095, USA
| | - P Huck
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T J Humanic
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Igo
- University of California, Los Angeles, California 90095, USA
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - H Jang
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - K Jiang
- University of Science and Technology of China, Hefei 230026, China
| | - E G Judd
- University of California, Berkeley, California 94720, USA
| | - S Kabana
- Kent State University, Kent, Ohio 44242, USA
| | - D Kalinkin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - K Kang
- Tsinghua University, Beijing 100084, China
| | - K Kauder
- Wayne State University, Detroit, Michigan 48201, USA
| | - H W Ke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Keane
- Kent State University, Kent, Ohio 44242, USA
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - Z H Khan
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - D P Kikola
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - I Kisel
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - A Kisiel
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Kochenda
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D D Koetke
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - T Kollegger
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | | | - A F Kraishan
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - P Kravtsov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - K Krueger
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Kulakov
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - L Kumar
- Panjab University, Chandigarh 160014, India
| | - R A Kycia
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - M A C Lamont
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K D Landry
- University of California, Los Angeles, California 90095, USA
| | - J Lauret
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Li
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Li
- University of Science and Technology of China, Hefei 230026, China
| | - W Li
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Z M Li
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Li
- Tsinghua University, Beijing 100084, China
| | - X Li
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M A Lisa
- Ohio State University, Columbus, Ohio 43210, USA
| | - F Liu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W J Llope
- Wayne State University, Detroit, Michigan 48201, USA
| | - M Lomnitz
- Kent State University, Kent, Ohio 44242, USA
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Luo
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y G Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - G L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - R Ma
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Magdy
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - R Majka
- Yale University, New Haven, Connecticut 06520, USA
| | - A Manion
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Margetis
- Kent State University, Kent, Ohio 44242, USA
| | - C Markert
- University of Texas, Austin, Texas 78712, USA
| | - H Masui
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D McDonald
- University of Houston, Houston, Texas 77204, USA
| | - K Meehan
- University of California, Davis, California 95616, USA
| | - N G Minaev
- Institute of High Energy Physics, Protvino 142281, Russia
| | | | - B Mohanty
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - M M Mondal
- Texas A&M University, College Station, Texas 77843, USA
| | - D Morozov
- Institute of High Energy Physics, Protvino 142281, Russia
| | - M K Mustafa
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B K Nandi
- Indian Institute of Technology, Mumbai 400076, India
| | - Md Nasim
- University of California, Los Angeles, California 90095, USA
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - G Nigmatkulov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - L V Nogach
- Institute of High Energy Physics, Protvino 142281, Russia
| | - S Y Noh
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - J Novak
- Michigan State University, East Lansing, Michigan 48824, USA
| | - S B Nurushev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Oh
- Pusan National University, Pusan 609735, Republic of Korea
| | - V Okorokov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D Olvitt
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - B S Page
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Pak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y X Pan
- University of California, Los Angeles, California 90095, USA
| | - Y Pandit
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - Y Panebratsev
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - B Pawlik
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - H Pei
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Perkins
- University of California, Berkeley, California 94720, USA
| | - A Peterson
- Ohio State University, Columbus, Ohio 43210, USA
| | - P Pile
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Planinic
- University of Zagreb, Zagreb HR-10002, Croatia
| | - J Pluta
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - N Poljak
- University of Zagreb, Zagreb HR-10002, Croatia
| | - K Poniatowska
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Posik
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A M Poskanzer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N K Pruthi
- Panjab University, Chandigarh 160014, India
| | - J Putschke
- Wayne State University, Detroit, Michigan 48201, USA
| | - H Qiu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Quintero
- Kent State University, Kent, Ohio 44242, USA
| | - S Ramachandran
- University of Kentucky, Lexington, Kentucky, 40506-0055, USA
| | - R Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - S Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R L Ray
- University of Texas, Austin, Texas 78712, USA
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | - J L Romero
- University of California, Davis, California 95616, USA
| | - A Roy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Rusnak
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - O Rusnakova
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - N R Sahoo
- Texas A&M University, College Station, Texas 77843, USA
| | - P K Sahu
- Institute of Physics, Bhubaneswar 751005, India
| | - I Sakrejda
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Salur
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Sandweiss
- Yale University, New Haven, Connecticut 06520, USA
| | - A Sarkar
- Indian Institute of Technology, Mumbai 400076, India
| | - J Schambach
- University of Texas, Austin, Texas 78712, USA
| | | | - A M Schmah
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Schmitz
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178, USA
| | - P Seyboth
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - N Shah
- University of California, Los Angeles, California 90095, USA
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | | | - M Shao
- University of Science and Technology of China, Hefei 230026, China
| | - M K Sharma
- University of Jammu, Jammu 180001, India
| | - B Sharma
- Panjab University, Chandigarh 160014, India
| | - W Q Shen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S S Shi
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Q Y Shou
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E P Sichtermann
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Sikora
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - M Simko
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M J Skoby
- Indiana University, Bloomington, Indiana 47408, USA
| | - D Smirnov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Smirnov
- Yale University, New Haven, Connecticut 06520, USA
| | - L Song
- University of Houston, Houston, Texas 77204, USA
| | - P Sorensen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H M Spinka
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - M Stepanov
- Purdue University, West Lafayette, Indiana 47907, USA
| | - R Stock
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - M Strikhanov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | | | - M Sumbera
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - B Summa
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Z Sun
- Institute of Modern Physics, Lanzhou 730000, China
| | - X M Sun
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Sun
- University of Science and Technology of China, Hefei 230026, China
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - M A Szelezniak
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Tang
- University of Science and Technology of China, Hefei 230026, China
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824, USA
| | - A N Tawfik
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Timmins
- University of Houston, Houston, Texas 77204, USA
| | - D Tlusty
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M Tokarev
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - S Trentalange
- University of California, Los Angeles, California 90095, USA
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843, USA
| | - P Tribedy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | | | - B A Trzeciak
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - O D Tsai
- University of California, Los Angeles, California 90095, USA
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Upsal
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | - R Varma
- Indian Institute of Technology, Mumbai 400076, India
| | - A N Vasiliev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - R Vertesi
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y P Viyogi
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - S A Voloshin
- Wayne State University, Detroit, Michigan 48201, USA
| | - A Vossen
- Indiana University, Bloomington, Indiana 47408, USA
| | - G Wang
- University of California, Los Angeles, California 90095, USA
| | - Y Wang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - F Wang
- Purdue University, West Lafayette, Indiana 47907, USA
| | - Y Wang
- Tsinghua University, Beijing 100084, China
| | - H Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J S Wang
- Institute of Modern Physics, Lanzhou 730000, China
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Wen
- University of California, Los Angeles, California 90095, USA
| | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824, USA
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408, USA
| | - R Witt
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - Y F Wu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z G Xiao
- Tsinghua University, Beijing 100084, China
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Xin
- Rice University, Houston, Texas 77251, USA
| | - Q H Xu
- Shandong University, Jinan, Shandong 250100, China
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H Xu
- Institute of Modern Physics, Lanzhou 730000, China
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Y F Xu
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Q Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Y Yang
- Institute of Modern Physics, Lanzhou 730000, China
| | - S Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Y Yang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - P Yepes
- Rice University, Houston, Texas 77251, USA
| | - L Yi
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I-K Yoo
- Pusan National University, Pusan 609735, Republic of Korea
| | - N Yu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - H Zbroszczyk
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - W Zha
- University of Science and Technology of China, Hefei 230026, China
| | - X P Zhang
- Tsinghua University, Beijing 100084, China
| | - J Zhang
- Shandong University, Jinan, Shandong 250100, China
| | - Y Zhang
- University of Science and Technology of China, Hefei 230026, China
| | - J Zhang
- Institute of Modern Physics, Lanzhou 730000, China
| | - J B Zhang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - S Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Z Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - J Zhao
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Zhong
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Zhou
- University of Science and Technology of China, Hefei 230026, China
| | - X Zhu
- Tsinghua University, Beijing 100084, China
| | - Y Zoulkarneeva
- Joint Institute for Nuclear Research, Dubna, 141 980, Russia
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| |
Collapse
|
28
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Alford J, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Banerjee A, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Bouchet J, Brandin AV, Bunzarov I, Burton TP, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Cervantes MC, Chakaberia I, Chaloupka P, Chang Z, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Das S, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, di Ruzza B, Didenko L, Dilks C, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Eppley G, Esha R, Evdokimov O, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Z, Filip P, Fisyak Y, Flores CE, Fulek L, Gagliardi CA, Garand D, Geurts F, Gibson A, Girard M, Greiner L, Grosnick D, Gunarathne DS, Guo Y, Gupta S, Gupta A, Guryn W, Hamad A, Hamed A, Haque R, Harris JW, He L, Heppelmann S, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang HZ, Huang B, Huang X, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Jiang K, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Khan ZH, Kikola DP, Kisel I, Kisiel A, Koetke DD, Kollegger T, Kosarzewski LK, Kotchenda L, Kraishan AF, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Li W, Li Y, Li C, Li ZM, Li X, Li X, Lisa MA, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Ma L, Ma R, Ma YG, Ma GL, Magdy N, Majka R, Manion A, Margetis S, Markert C, Masui H, Matis HS, McDonald D, Meehan K, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nigmatkulov G, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Okorokov V, Olvitt DL, Page BS, Pak R, Pan YX, Pandit Y, Panebratsev Y, Pawlik B, Pei H, Perkins C, Peterson A, Pile P, Planinic M, Pluta J, Poljak N, Poniatowska K, Porter J, Posik M, Poskanzer AM, Pruthi NK, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala S, Raniwala R, Ray RL, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Roy A, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandweiss J, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Sharma MK, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Sikora R, Simko M, Skoby MJ, Smirnov D, Smirnov N, Song L, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stepanov M, Stock R, Strikhanov M, Stringfellow B, Sumbera M, Summa BJ, Sun X, Sun XM, Sun Z, Sun Y, Surrow B, Svirida DN, Szelezniak MA, Tang Z, Tang AH, Tarnowsky T, Tawfik AN, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Trzeciak BA, Tsai OD, Ullrich T, Underwood DG, Upsal I, Van Buren G, van Nieuwenhuizen G, Vandenbroucke M, Varma R, Vasiliev AN, Vertesi R, Videbaek F, Viyogi YP, Vokal S, Voloshin SA, Vossen A, Wang F, Wang Y, Wang H, Wang JS, Wang Y, Wang G, Webb G, Webb JC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Xiao Z, Xie W, Xin K, Xu YF, Xu N, Xu Z, Xu QH, Xu H, Yang Y, Yang Y, Yang C, Yang S, Yang Q, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang XP, Zhang JB, Zhang J, Zhang Z, Zhang S, Zhang Y, Zhang JL, Zhao F, Zhao J, Zhong C, Zhou L, Zhu X, Zoulkarneeva Y, Zyzak M. Azimuthal Anisotropy in U+U and Au+Au Collisions at RHIC. Phys Rev Lett 2015; 115:222301. [PMID: 26650297 DOI: 10.1103/physrevlett.115.222301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Indexed: 06/05/2023]
Abstract
Collisions between prolate uranium nuclei are used to study how particle production and azimuthal anisotropies depend on initial geometry in heavy-ion collisions. We report the two- and four-particle cumulants, v_{2}{2} and v_{2}{4}, for charged hadrons from U+U collisions at sqrt[s_{NN}]=193 GeV and Au+Au collisions at sqrt[s_{NN}]=200 GeV. Nearly fully overlapping collisions are selected based on the energy deposited by spectators in zero degree calorimeters (ZDCs). Within this sample, the observed dependence of v_{2}{2} on multiplicity demonstrates that ZDC information combined with multiplicity can preferentially select different overlap configurations in U+U collisions. We also show that v_{2} vs multiplicity can be better described by models, such as gluon saturation or quark participant models, that eliminate the dependence of the multiplicity on the number of binary nucleon-nucleon collisions.
Collapse
Affiliation(s)
- L Adamczyk
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - J K Adkins
- University of Kentucky, Lexington, Kentucky, 40506-0055, USA
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - J Alford
- Kent State University, Kent, Ohio 44242, USA
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - D Arkhipkin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E C Aschenauer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Averichev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - A Banerjee
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - R Bellwied
- University of Houston, Houston, Texas 77204, USA
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - A K Bhati
- Panjab University, Chandigarh 160014, India
| | - P Bhattarai
- University of Texas, Austin, Texas 78712, USA
| | - J Bielcik
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - J Bielcikova
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - L C Bland
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - J Bouchet
- Kent State University, Kent, Ohio 44242, USA
| | - A V Brandin
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - I Bunzarov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - T P Burton
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | - H Caines
- Yale University, New Haven, Connecticut 06520, USA
| | | | - J M Campbell
- Ohio State University, Columbus, Ohio 43210, USA
| | - D Cebra
- University of California, Davis, California 95616, USA
| | - M C Cervantes
- Texas A&M University, College Station, Texas 77843, USA
| | - I Chakaberia
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Chaloupka
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - Z Chang
- Texas A&M University, College Station, Texas 77843, USA
| | | | - J H Chen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Chen
- Institute of Modern Physics, Lanzhou 730000, China
| | - J Cheng
- Tsinghua University, Beijing 100084, China
| | - M Cherney
- Creighton University, Omaha, Nebraska 68178, USA
| | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Contin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H J Crawford
- University of California, Berkeley, California 94720, USA
| | - S Das
- Institute of Physics, Bhubaneswar 751005, India
| | - L C De Silva
- Creighton University, Omaha, Nebraska 68178, USA
| | - R R Debbe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Deng
- Shandong University, Jinan, Shandong 250100, China
| | | | - B di Ruzza
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Dilks
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J E Draper
- University of California, Davis, California 95616, USA
| | - C M Du
- Institute of Modern Physics, Lanzhou 730000, China
| | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L G Efimov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Engelage
- University of California, Berkeley, California 94720, USA
| | - G Eppley
- Rice University, Houston, Texas 77251, USA
| | - R Esha
- University of California, Los Angeles, California 90095, USA
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - O Eyser
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky, 40506-0055, USA
| | - S Fazio
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Federic
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - J Fedorisin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Z Feng
- Central China Normal University (HZNU), Wuhan 430079, China
| | - P Filip
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C E Flores
- University of California, Davis, California 95616, USA
| | - L Fulek
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - C A Gagliardi
- Texas A&M University, College Station, Texas 77843, USA
| | - D Garand
- Purdue University, West Lafayette, Indiana 47907, USA
| | - F Geurts
- Rice University, Houston, Texas 77251, USA
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - M Girard
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Greiner
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - D S Gunarathne
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - Y Guo
- University of Science and Technology of China, Hefei 230026, China
| | - S Gupta
- University of Jammu, Jammu 180001, India
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - W Guryn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Hamad
- Kent State University, Kent, Ohio 44242, USA
| | - A Hamed
- Texas A&M University, College Station, Texas 77843, USA
| | - R Haque
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - J W Harris
- Yale University, New Haven, Connecticut 06520, USA
| | - L He
- Purdue University, West Lafayette, Indiana 47907, USA
| | - S Heppelmann
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Heppelmann
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Hirsch
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - D J Hofman
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - S Horvat
- Yale University, New Haven, Connecticut 06520, USA
| | - H Z Huang
- University of California, Los Angeles, California 90095, USA
| | - B Huang
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - X Huang
- Tsinghua University, Beijing 100084, China
| | - P Huck
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T J Humanic
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Igo
- University of California, Los Angeles, California 90095, USA
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - H Jang
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - K Jiang
- University of Science and Technology of China, Hefei 230026, China
| | - E G Judd
- University of California, Berkeley, California 94720, USA
| | - S Kabana
- Kent State University, Kent, Ohio 44242, USA
| | - D Kalinkin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - K Kang
- Tsinghua University, Beijing 100084, China
| | - K Kauder
- Wayne State University, Detroit, Michigan 48201, USA
| | - H W Ke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Keane
- Kent State University, Kent, Ohio 44242, USA
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Z H Khan
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - D P Kikola
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - I Kisel
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - A Kisiel
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - D D Koetke
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - T Kollegger
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | | | - L Kotchenda
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - A F Kraishan
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - P Kravtsov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - K Krueger
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Kulakov
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - L Kumar
- Panjab University, Chandigarh 160014, India
| | - R A Kycia
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - M A C Lamont
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K D Landry
- University of California, Los Angeles, California 90095, USA
| | - J Lauret
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Li
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y Li
- Tsinghua University, Beijing 100084, China
| | - C Li
- University of Science and Technology of China, Hefei 230026, China
| | - Z M Li
- Central China Normal University (HZNU), Wuhan 430079, China
| | - X Li
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - X Li
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M A Lisa
- Ohio State University, Columbus, Ohio 43210, USA
| | - F Liu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W J Llope
- Wayne State University, Detroit, Michigan 48201, USA
| | - M Lomnitz
- Kent State University, Kent, Ohio 44242, USA
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Luo
- Central China Normal University (HZNU), Wuhan 430079, China
| | - L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - R Ma
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y G Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - G L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - N Magdy
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - R Majka
- Yale University, New Haven, Connecticut 06520, USA
| | - A Manion
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Margetis
- Kent State University, Kent, Ohio 44242, USA
| | - C Markert
- University of Texas, Austin, Texas 78712, USA
| | - H Masui
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D McDonald
- University of Houston, Houston, Texas 77204, USA
| | - K Meehan
- University of California, Davis, California 95616, USA
| | - N G Minaev
- Institute of High Energy Physics, Protvino 142281, Russia
| | | | - B Mohanty
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - M M Mondal
- Texas A&M University, College Station, Texas 77843, USA
| | - D A Morozov
- Institute of High Energy Physics, Protvino 142281, Russia
| | - M K Mustafa
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B K Nandi
- Indian Institute of Technology, Mumbai 400076, India
| | - Md Nasim
- University of California, Los Angeles, California 90095, USA
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - G Nigmatkulov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - L V Nogach
- Institute of High Energy Physics, Protvino 142281, Russia
| | - S Y Noh
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - J Novak
- Michigan State University, East Lansing, Michigan 48824, USA
| | - S B Nurushev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Oh
- Pusan National University, Pusan 609735, Republic of Korea
| | - V Okorokov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D L Olvitt
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - B S Page
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Pak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y X Pan
- University of California, Los Angeles, California 90095, USA
| | - Y Pandit
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - Y Panebratsev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - B Pawlik
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - H Pei
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Perkins
- University of California, Berkeley, California 94720, USA
| | - A Peterson
- Ohio State University, Columbus, Ohio 43210, USA
| | - P Pile
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Planinic
- University of Zagreb, Zagreb HR-10002, Croatia
| | - J Pluta
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - N Poljak
- University of Zagreb, Zagreb HR-10002, Croatia
| | - K Poniatowska
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Posik
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A M Poskanzer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N K Pruthi
- Panjab University, Chandigarh 160014, India
| | - J Putschke
- Wayne State University, Detroit, Michigan 48201, USA
| | - H Qiu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Quintero
- Kent State University, Kent, Ohio 44242, USA
| | - S Ramachandran
- University of Kentucky, Lexington, Kentucky, 40506-0055, USA
| | - S Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R L Ray
- University of Texas, Austin, Texas 78712, USA
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | - J L Romero
- University of California, Davis, California 95616, USA
| | - A Roy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Rusnak
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - O Rusnakova
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - N R Sahoo
- Texas A&M University, College Station, Texas 77843, USA
| | - P K Sahu
- Institute of Physics, Bhubaneswar 751005, India
| | - I Sakrejda
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Salur
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Sandweiss
- Yale University, New Haven, Connecticut 06520, USA
| | - A Sarkar
- Indian Institute of Technology, Mumbai 400076, India
| | - J Schambach
- University of Texas, Austin, Texas 78712, USA
| | | | - A M Schmah
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Schmitz
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178, USA
| | - P Seyboth
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - N Shah
- University of California, Los Angeles, California 90095, USA
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - M Shao
- University of Science and Technology of China, Hefei 230026, China
| | - B Sharma
- Panjab University, Chandigarh 160014, India
| | - M K Sharma
- University of Jammu, Jammu 180001, India
| | - W Q Shen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S S Shi
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Q Y Shou
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E P Sichtermann
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Sikora
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - M Simko
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M J Skoby
- Indiana University, Bloomington, Indiana 47408, USA
| | - D Smirnov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Smirnov
- Yale University, New Haven, Connecticut 06520, USA
| | - L Song
- University of Houston, Houston, Texas 77204, USA
| | - P Sorensen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H M Spinka
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - M Stepanov
- Purdue University, West Lafayette, Indiana 47907, USA
| | - R Stock
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - M Strikhanov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | | | - M Sumbera
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - B J Summa
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - X M Sun
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z Sun
- Institute of Modern Physics, Lanzhou 730000, China
| | - Y Sun
- University of Science and Technology of China, Hefei 230026, China
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - M A Szelezniak
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Z Tang
- University of Science and Technology of China, Hefei 230026, China
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824, USA
| | - A N Tawfik
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Timmins
- University of Houston, Houston, Texas 77204, USA
| | - D Tlusty
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S Trentalange
- University of California, Los Angeles, California 90095, USA
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843, USA
| | - P Tribedy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | | | - B A Trzeciak
- Czech Technical University in Prague, FNSPE, Prague, 115 19, Czech Republic
| | - O D Tsai
- University of California, Los Angeles, California 90095, USA
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Upsal
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | - R Varma
- Indian Institute of Technology, Mumbai 400076, India
| | - A N Vasiliev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - R Vertesi
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - F Videbaek
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y P Viyogi
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S A Voloshin
- Wayne State University, Detroit, Michigan 48201, USA
| | - A Vossen
- Indiana University, Bloomington, Indiana 47408, USA
| | - F Wang
- Purdue University, West Lafayette, Indiana 47907, USA
| | - Y Wang
- Tsinghua University, Beijing 100084, China
| | - H Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J S Wang
- Institute of Modern Physics, Lanzhou 730000, China
| | - Y Wang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - G Wang
- University of California, Los Angeles, California 90095, USA
| | - G Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Wen
- University of California, Los Angeles, California 90095, USA
| | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824, USA
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408, USA
| | - R Witt
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - Y F Wu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z Xiao
- Tsinghua University, Beijing 100084, China
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Xin
- Rice University, Houston, Texas 77251, USA
| | - Y F Xu
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Q H Xu
- Shandong University, Jinan, Shandong 250100, China
| | - H Xu
- Institute of Modern Physics, Lanzhou 730000, China
| | - Y Yang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Yang
- Institute of Modern Physics, Lanzhou 730000, China
| | - C Yang
- University of Science and Technology of China, Hefei 230026, China
| | - S Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Q Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - P Yepes
- Rice University, Houston, Texas 77251, USA
| | - L Yi
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I-K Yoo
- Pusan National University, Pusan 609735, Republic of Korea
| | - N Yu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - H Zbroszczyk
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - W Zha
- University of Science and Technology of China, Hefei 230026, China
| | - X P Zhang
- Tsinghua University, Beijing 100084, China
| | - J B Zhang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - J Zhang
- Institute of Modern Physics, Lanzhou 730000, China
| | - Z Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y Zhang
- University of Science and Technology of China, Hefei 230026, China
| | - J L Zhang
- Shandong University, Jinan, Shandong 250100, China
| | - F Zhao
- University of California, Los Angeles, California 90095, USA
| | - J Zhao
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Zhong
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Zhou
- University of Science and Technology of China, Hefei 230026, China
| | - X Zhu
- Tsinghua University, Beijing 100084, China
| | - Y Zoulkarneeva
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| |
Collapse
|
29
|
Grice J, Reid A, Peterson A, Blackburn K, Tubbs L, Lord S, Huber P, Horricks R, Dixon B, Bols NC, Lumsden JS. Walleye Sander vitreus (Mitchill) are relatively resistant to experimental infection with VHSV IVb and extant walleye strains vary in susceptibility. J Fish Dis 2015; 38:859-872. [PMID: 25219756 DOI: 10.1111/jfd.12298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 07/03/2014] [Accepted: 05/07/2014] [Indexed: 06/03/2023]
Abstract
Compared to fathead minnow, walleye demonstrate low susceptibility to experimental infection with VHSV IVb, regardless of route of exposure or water temperature at time of infection. In triplicate and duplicate groups, walleye were intraperitoneally (i.p.) injected (102 -108 pfu/fish) or waterborne-exposed (w; 1.4 × 107 pfu mL-1 ) with VHSV IVb. High cumulative mortality (64-100%) and severe gross lesions associated with VHSV IVb infection were evident only in fish i.p. injected with 108 pfu at 12 °C. These fish had multifocal necrosis of several tissues including the gill and heart. There was no difference in mortality between walleye infected (w or i.p.) at 12 °C (spring stocking) compared with a declining temperature profile from 18 to 12 °C (fall stocking). There were significant differences (P < 0.05) in mortality between four extant walleye strains following i.p. infection, indicating that the choice of walleye strain for stocking might be an important consideration. Viral antigen was found in both i.p. and w-exposed walleye using immunohistochemistry, mostly within the gill and skin of w-exposed fish and most prominently in dermal fibrocytes. VHSV IVb was detected in multiple tissues from 6 to 21 days post-infection using reverse transcriptase quantitative polymerase chain reaction (RT-qPCR).
Collapse
Affiliation(s)
- J Grice
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - A Reid
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - A Peterson
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - K Blackburn
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - L Tubbs
- Department of Biology, University of Waterloo, Waterloo, ON, Canada
| | - S Lord
- Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON, Canada
| | - P Huber
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - R Horricks
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - B Dixon
- Novartis Animal Health Inc., Victoria, PEI, Canada
| | - N C Bols
- Novartis Animal Health Inc., Victoria, PEI, Canada
| | - J S Lumsden
- Fish Pathology Laboratory, Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| |
Collapse
|
30
|
Cortes J, Crown J, Awada A, Schmid P, Gianni L, Garcia-Estevez L, Martinez-Janez N, Chan S, Steinberg J, Blaney M, Tudor I, Uppal H, Peterson A, Miller K, Yardley D, Hudis C, Traina T. 1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30756-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Montgomery B, Joshua A, Gleave M, Fleshner N, Bubley G, True L, Tretiakova M, Wu K, Novotny W, Peterson A, Amelsberg A, Taplin M. 2501 ORAL A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31323-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Tracey L, D'Abrera V, McCann R, Peterson A, Armstrong P. Analysis of Hip and Knee Arthroplasty Surgical Site Infection Data in Western Australia: Null Effect of Stratification by Procedure Type. Infect Control Hosp Epidemiol 2015; 33:313-5. [DOI: 10.1086/664059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
33
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Alford J, Anson CD, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Balewski J, Banerjee A, Barnovska Z, Beavis DR, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bichsel H, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Borowski W, Bouchet J, Brandin AV, Brovko SG, Bültmann S, Bunzarov I, Burton TP, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Cendejas R, Cervantes MC, Chaloupka P, Chang Z, Chattopadhyay S, Chen HF, Chen JH, Chen L, Cheng J, Cherney M, Chikanian A, Christie W, Chwastowski J, Codrington MJM, Corliss R, Cramer JG, Crawford HJ, Cui X, Das S, Davila Leyva A, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, Derradi de Souza R, Dhamija S, di Ruzza B, Didenko L, Dilks C, Ding F, Djawotho P, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Engle KS, Eppley G, Eun L, Evdokimov O, Fatemi R, Fazio S, Fedorisin J, Filip P, Finch E, Fisyak Y, Flores CE, Gagliardi CA, Gangadharan DR, Garand D, Geurts F, Gibson A, Girard M, Gliske S, Grosnick D, Guo Y, Gupta A, Gupta S, Guryn W, Haag B, Hajkova O, Hamed A, Han LX, Haque R, Harris JW, Hays-Wehle JP, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang B, Huang HZ, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Kesich A, Khan ZH, Kikola DP, Kisel I, Kisiel A, Koetke DD, Kollegger T, Konzer J, Koralt I, Korsch W, Kotchenda L, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Leight W, LeVine MJ, Li C, Li W, Li X, Li X, Li Y, Li ZM, Lima LM, Lisa MA, Liu F, Ljubicic T, Llope WJ, Longacre RS, Luo X, Ma GL, Ma YG, Madagodagettige Don DMMD, Mahapatra DP, Majka R, Margetis S, Markert C, Masui H, Matis HS, McDonald D, McShane TS, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Morozov DA, Munhoz MG, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nelson JM, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Ohlson A, Okorokov V, Oldag EW, Oliveira RAN, Pachr M, Page BS, Pal SK, Pan YX, Pandit Y, Panebratsev Y, Pawlak T, Pawlik B, Pei H, Perkins C, Peryt W, Peterson A, Pile P, Planinic M, Pluta J, Plyku D, Poljak N, Porter J, Poskanzer AM, Pruthi NK, Przybycien M, Pujahari PR, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Riley CK, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ross JF, Roy A, Ruan L, Rusnak J, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandacz A, Sandweiss J, Sangaline E, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Singaraju RN, Skoby MJ, Smirnov D, Smirnov N, Solanki D, Sorensen P, deSouza UG, Spinka HM, Srivastava B, Stanislaus TDS, Stevens JR, Stock R, Strikhanov M, Stringfellow B, Suaide AAP, Sumbera M, Sun X, Sun XM, Sun Y, Sun Z, Surrow B, Svirida DN, Symons TJM, Szanto de Toledo A, Takahashi J, Tang AH, Tang Z, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Trzeciak BA, Tsai OD, Turnau J, Ullrich T, Underwood DG, Van Buren G, van Nieuwenhuizen G, Vanfossen JA, Varma R, Vasconcelos GMS, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Vossen A, Wada M, Walker M, Wang F, Wang G, Wang H, Wang JS, Wang XL, Wang Y, Wang Y, Webb G, Webb JC, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Xiao Z, Xie W, Xin K, Xu H, Xu N, Xu QH, Xu Y, Xu Z, Yan W, Yang C, Yang Y, Yang Y, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Zawisza Y, Zbroszczyk H, Zha W, Zhang JB, Zhang S, Zhang XP, Zhang Y, Zhang ZP, Zhao F, Zhao J, Zhong C, Zhu X, Zhu YH, Zoulkarneeva Y, Zyzak M. Beam energy dependence of moments of the net-charge multiplicity distributions in Au+Au collisions at RHIC. Phys Rev Lett 2014; 113:092301. [PMID: 25215979 DOI: 10.1103/physrevlett.113.092301] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Indexed: 06/03/2023]
Abstract
We report the first measurements of the moments--mean (M), variance (σ(2)), skewness (S), and kurtosis (κ)--of the net-charge multiplicity distributions at midrapidity in Au+Au collisions at seven energies, ranging from sqrt[sNN]=7.7 to 200 GeV, as a part of the Beam Energy Scan program at RHIC. The moments are related to the thermodynamic susceptibilities of net charge, and are sensitive to the location of the QCD critical point. We compare the products of the moments, σ(2)/M, Sσ, and κσ(2), with the expectations from Poisson and negative binomial distributions (NBDs). The Sσ values deviate from the Poisson baseline and are close to the NBD baseline, while the κσ(2) values tend to lie between the two. Within the present uncertainties, our data do not show nonmonotonic behavior as a function of collision energy. These measurements provide a valuable tool to extract the freeze-out parameters in heavy-ion collisions by comparing with theoretical models.
Collapse
Affiliation(s)
- L Adamczyk
- AGH University of Science and Technology, Cracow, Poland
| | - J K Adkins
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - J Alford
- Kent State University, Kent, Ohio 44242, USA
| | - C D Anson
- Ohio State University, Columbus, Ohio 43210, USA
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - D Arkhipkin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E C Aschenauer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Averichev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Balewski
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - A Banerjee
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - Z Barnovska
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - D R Beavis
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Bellwied
- University of Houston, Houston, Texas 77204, USA
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - A K Bhati
- Panjab University, Chandigarh 160014, India
| | - P Bhattarai
- University of Texas, Austin, Texas 78712, USA
| | - H Bichsel
- University of Washington, Seattle, Washington 98195, USA
| | - J Bielcik
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - J Bielcikova
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - L C Bland
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | | | - J Bouchet
- Kent State University, Kent, Ohio 44242, USA
| | - A V Brandin
- Moscow Engineering Physics Institute, Moscow, Russia
| | - S G Brovko
- University of California, Davis, California 95616, USA
| | - S Bültmann
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - I Bunzarov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - T P Burton
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | - H Caines
- Yale University, New Haven, Connecticut 06520, USA
| | | | - D Cebra
- University of California, Davis, California 95616, USA
| | - R Cendejas
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M C Cervantes
- Texas A&M University, College Station, Texas 77843, USA
| | - P Chaloupka
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - Z Chang
- Texas A&M University, College Station, Texas 77843, USA
| | | | - H F Chen
- University of Science & Technology of China, Hefei 230026, China
| | - J H Chen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Chen
- Central China Normal University (HZNU), Wuhan 430079, China
| | - J Cheng
- Tsinghua University, Beijing 100084, China
| | - M Cherney
- Creighton University, Omaha, Nebraska 68178, USA
| | - A Chikanian
- Yale University, New Haven, Connecticut 06520, USA
| | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | - R Corliss
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - J G Cramer
- University of Washington, Seattle, Washington 98195, USA
| | - H J Crawford
- University of California, Berkeley, California 94720, USA
| | - X Cui
- University of Science & Technology of China, Hefei 230026, China
| | - S Das
- Institute of Physics, Bhubaneswar 751005, India
| | | | - L C De Silva
- University of Houston, Houston, Texas 77204, USA
| | - R R Debbe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Deng
- Shandong University, Jinan, Shandong 250100, China
| | | | | | - S Dhamija
- Indiana University, Bloomington, Indiana 47408, USA
| | - B di Ruzza
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Dilks
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - F Ding
- University of California, Davis, California 95616, USA
| | - P Djawotho
- Texas A&M University, College Station, Texas 77843, USA
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J E Draper
- University of California, Davis, California 95616, USA
| | - C M Du
- Institute of Modern Physics, Lanzhou, China
| | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L G Efimov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Engelage
- University of California, Berkeley, California 94720, USA
| | - K S Engle
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - G Eppley
- Rice University, Houston, Texas 77251, USA
| | - L Eun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - S Fazio
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Fedorisin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - P Filip
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - E Finch
- Yale University, New Haven, Connecticut 06520, USA
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C E Flores
- University of California, Davis, California 95616, USA
| | - C A Gagliardi
- Texas A&M University, College Station, Texas 77843, USA
| | | | - D Garand
- Purdue University, West Lafayette, Indiana 47907, USA
| | - F Geurts
- Rice University, Houston, Texas 77251, USA
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - M Girard
- Warsaw University of Technology, Warsaw, Poland
| | - S Gliske
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - Y Guo
- University of Science & Technology of China, Hefei 230026, China
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - S Gupta
- University of Jammu, Jammu 180001, India
| | - W Guryn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Haag
- University of California, Davis, California 95616, USA
| | - O Hajkova
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - A Hamed
- Texas A&M University, College Station, Texas 77843, USA
| | - L-X Han
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - R Haque
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - J W Harris
- Yale University, New Haven, Connecticut 06520, USA
| | - J P Hays-Wehle
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - S Heppelmann
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Hirsch
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - D J Hofman
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - S Horvat
- Yale University, New Haven, Connecticut 06520, USA
| | - B Huang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H Z Huang
- University of California, Los Angeles, California 90095, USA
| | - P Huck
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T J Humanic
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Igo
- University of California, Los Angeles, California 90095, USA
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - H Jang
- Korea Institute of Science and Technology Information, Daejeon, Korea
| | - E G Judd
- University of California, Berkeley, California 94720, USA
| | | | - D Kalinkin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - K Kang
- Tsinghua University, Beijing 100084, China
| | - K Kauder
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - H W Ke
- Central China Normal University (HZNU), Wuhan 430079, China
| | - D Keane
- Kent State University, Kent, Ohio 44242, USA
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - A Kesich
- University of California, Davis, California 95616, USA
| | - Z H Khan
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - D P Kikola
- Purdue University, West Lafayette, Indiana 47907, USA
| | - I Kisel
- Frankfurt Institute for Advanced Studies FIAS, Germany
| | - A Kisiel
- Warsaw University of Technology, Warsaw, Poland
| | - D D Koetke
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - T Kollegger
- Frankfurt Institute for Advanced Studies FIAS, Germany
| | - J Konzer
- Purdue University, West Lafayette, Indiana 47907, USA
| | - I Koralt
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Korsch
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - L Kotchenda
- Moscow Engineering Physics Institute, Moscow, Russia
| | - P Kravtsov
- Moscow Engineering Physics Institute, Moscow, Russia
| | - K Krueger
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Kulakov
- Frankfurt Institute for Advanced Studies FIAS, Germany
| | - L Kumar
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - R A Kycia
- Cracow University of Technology, Cracow, Poland
| | - M A C Lamont
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K D Landry
- University of California, Los Angeles, California 90095, USA
| | - J Lauret
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Leight
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - M J LeVine
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Li
- University of Science & Technology of China, Hefei 230026, China
| | - W Li
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Li
- Purdue University, West Lafayette, Indiana 47907, USA
| | - X Li
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - Y Li
- Tsinghua University, Beijing 100084, China
| | - Z M Li
- Central China Normal University (HZNU), Wuhan 430079, China
| | - L M Lima
- Universidade de Sao Paulo, Sao Paulo, Brazil
| | - M A Lisa
- Ohio State University, Columbus, Ohio 43210, USA
| | - F Liu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W J Llope
- Rice University, Houston, Texas 77251, USA
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Luo
- Central China Normal University (HZNU), Wuhan 430079, China
| | - G L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y G Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | | | | | - R Majka
- Yale University, New Haven, Connecticut 06520, USA
| | - S Margetis
- Kent State University, Kent, Ohio 44242, USA
| | - C Markert
- University of Texas, Austin, Texas 78712, USA
| | - H Masui
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D McDonald
- Rice University, Houston, Texas 77251, USA
| | - T S McShane
- Creighton University, Omaha, Nebraska 68178, USA
| | - N G Minaev
- Institute of High Energy Physics, Protvino, Russia
| | | | - B Mohanty
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - M M Mondal
- Texas A&M University, College Station, Texas 77843, USA
| | - D A Morozov
- Institute of High Energy Physics, Protvino, Russia
| | - M G Munhoz
- Universidade de Sao Paulo, Sao Paulo, Brazil
| | - M K Mustafa
- Purdue University, West Lafayette, Indiana 47907, USA
| | - B K Nandi
- Indian Institute of Technology, Mumbai, India
| | - Md Nasim
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - J M Nelson
- University of Birmingham, Birmingham, United Kingdom
| | - L V Nogach
- Institute of High Energy Physics, Protvino, Russia
| | - S Y Noh
- Korea Institute of Science and Technology Information, Daejeon, Korea
| | - J Novak
- Michigan State University, East Lansing, Michigan 48824, USA
| | - S B Nurushev
- Institute of High Energy Physics, Protvino, Russia
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Oh
- Pusan National University, Pusan, Republic of Korea
| | - A Ohlson
- Yale University, New Haven, Connecticut 06520, USA
| | - V Okorokov
- Moscow Engineering Physics Institute, Moscow, Russia
| | - E W Oldag
- University of Texas, Austin, Texas 78712, USA
| | | | - M Pachr
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - B S Page
- Indiana University, Bloomington, Indiana 47408, USA
| | - S K Pal
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - Y X Pan
- University of California, Los Angeles, California 90095, USA
| | - Y Pandit
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - Y Panebratsev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - T Pawlak
- Warsaw University of Technology, Warsaw, Poland
| | - B Pawlik
- Institute of Nuclear Physics PAN, Cracow, Poland
| | - H Pei
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Perkins
- University of California, Berkeley, California 94720, USA
| | - W Peryt
- Warsaw University of Technology, Warsaw, Poland
| | - A Peterson
- Ohio State University, Columbus, Ohio 43210, USA
| | - P Pile
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Planinic
- University of Zagreb, Zagreb HR-10002, Croatia
| | - J Pluta
- Warsaw University of Technology, Warsaw, Poland
| | - D Plyku
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N Poljak
- University of Zagreb, Zagreb HR-10002, Croatia
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A M Poskanzer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N K Pruthi
- Panjab University, Chandigarh 160014, India
| | - M Przybycien
- AGH University of Science and Technology, Cracow, Poland
| | | | - H Qiu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Quintero
- Kent State University, Kent, Ohio 44242, USA
| | - S Ramachandran
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - R Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - S Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R L Ray
- University of Texas, Austin, Texas 78712, USA
| | - C K Riley
- Yale University, New Haven, Connecticut 06520, USA
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | - J L Romero
- University of California, Davis, California 95616, USA
| | - J F Ross
- Creighton University, Omaha, Nebraska 68178, USA
| | - A Roy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Rusnak
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - N R Sahoo
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - P K Sahu
- Institute of Physics, Bhubaneswar 751005, India
| | - I Sakrejda
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Salur
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Sandacz
- Warsaw University of Technology, Warsaw, Poland
| | - J Sandweiss
- Yale University, New Haven, Connecticut 06520, USA
| | - E Sangaline
- University of California, Davis, California 95616, USA
| | - A Sarkar
- Indian Institute of Technology, Mumbai, India
| | - J Schambach
- University of Texas, Austin, Texas 78712, USA
| | | | - A M Schmah
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Schmitz
- Max-Planck-Institut für Physik, Munich, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178, USA
| | - P Seyboth
- Max-Planck-Institut für Physik, Munich, Germany
| | - N Shah
- University of California, Los Angeles, California 90095, USA
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - M Shao
- University of Science & Technology of China, Hefei 230026, China
| | - B Sharma
- Panjab University, Chandigarh 160014, India
| | - W Q Shen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S S Shi
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Q Y Shou
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E P Sichtermann
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R N Singaraju
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - M J Skoby
- Indiana University, Bloomington, Indiana 47408, USA
| | - D Smirnov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Smirnov
- Yale University, New Haven, Connecticut 06520, USA
| | - D Solanki
- University of Rajasthan, Jaipur 302004, India
| | - P Sorensen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - U G deSouza
- Universidade de Sao Paulo, Sao Paulo, Brazil
| | - H M Spinka
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - J R Stevens
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - R Stock
- Frankfurt Institute for Advanced Studies FIAS, Germany
| | - M Strikhanov
- Moscow Engineering Physics Institute, Moscow, Russia
| | | | | | - M Sumbera
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - X Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - X M Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Y Sun
- University of Science & Technology of China, Hefei 230026, China
| | - Z Sun
- Institute of Modern Physics, Lanzhou, China
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - T J M Symons
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J Takahashi
- Universidade Estadual de Campinas, Sao Paulo, Brazil
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Tang
- University of Science & Technology of China, Hefei 230026, China
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824, USA
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Timmins
- University of Houston, Houston, Texas 77204, USA
| | - D Tlusty
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S Trentalange
- University of California, Los Angeles, California 90095, USA
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843, USA
| | - P Tribedy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | | | - O D Tsai
- University of California, Los Angeles, California 90095, USA
| | - J Turnau
- Institute of Nuclear Physics PAN, Cracow, Poland
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G van Nieuwenhuizen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | | | - R Varma
- Indian Institute of Technology, Mumbai, India
| | | | - A N Vasiliev
- Institute of High Energy Physics, Protvino, Russia
| | - R Vertesi
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y P Viyogi
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - A Vossen
- Indiana University, Bloomington, Indiana 47408, USA
| | - M Wada
- University of Texas, Austin, Texas 78712, USA
| | - M Walker
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - F Wang
- Purdue University, West Lafayette, Indiana 47907, USA
| | - G Wang
- University of California, Los Angeles, California 90095, USA
| | - H Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J S Wang
- Institute of Modern Physics, Lanzhou, China
| | - X L Wang
- University of Science & Technology of China, Hefei 230026, China
| | - Y Wang
- Tsinghua University, Beijing 100084, China
| | - Y Wang
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - G Webb
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824, USA
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408, USA
| | - R Witt
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - Y F Wu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z Xiao
- Tsinghua University, Beijing 100084, China
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Xin
- Rice University, Houston, Texas 77251, USA
| | - H Xu
- Institute of Modern Physics, Lanzhou, China
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Q H Xu
- Shandong University, Jinan, Shandong 250100, China
| | - Y Xu
- University of Science & Technology of China, Hefei 230026, China
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Yan
- Tsinghua University, Beijing 100084, China
| | - C Yang
- University of Science & Technology of China, Hefei 230026, China
| | - Y Yang
- Institute of Modern Physics, Lanzhou, China
| | - Y Yang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - P Yepes
- Rice University, Houston, Texas 77251, USA
| | - L Yi
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I-K Yoo
- Pusan National University, Pusan, Republic of Korea
| | - Y Zawisza
- University of Science & Technology of China, Hefei 230026, China
| | | | - W Zha
- University of Science & Technology of China, Hefei 230026, China
| | - J B Zhang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - S Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X P Zhang
- Tsinghua University, Beijing 100084, China
| | - Y Zhang
- University of Science & Technology of China, Hefei 230026, China
| | - Z P Zhang
- University of Science & Technology of China, Hefei 230026, China
| | - F Zhao
- University of California, Los Angeles, California 90095, USA
| | - J Zhao
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - C Zhong
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Zhu
- Tsinghua University, Beijing 100084, China
| | - Y H Zhu
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y Zoulkarneeva
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Germany
| |
Collapse
|
34
|
Black S, Peterson A. CT fluoroscopy guidance versus conventional CT guidance for percutaneous pulmonary nodule biopsy- a comparison of patient radiation exposure, procedural time, and complication rates. J Vasc Interv Radiol 2014. [DOI: 10.1016/j.jvir.2013.12.545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
35
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Alford J, Anson CD, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Balewski J, Banerjee A, Barnovska Z, Beavis DR, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bichsel H, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Borowski W, Bouchet J, Brandin AV, Brovko SG, Bültmann S, Bunzarov I, Burton TP, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Cendejas R, Cervantes MC, Chaloupka P, Chang Z, Chattopadhyay S, Chen HF, Chen JH, Chen L, Cheng J, Cherney M, Chikanian A, Christie W, Chwastowski J, Codrington MJM, Corliss R, Cramer JG, Crawford HJ, Cui X, Das S, Davila Leyva A, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, Derradi de Souza R, Dhamija S, di Ruzza B, Didenko L, Dilks C, Ding F, Djawotho P, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Engle KS, Eppley G, Eun L, Evdokimov O, Fatemi R, Fazio S, Fedorisin J, Filip P, Finch E, Fisyak Y, Flores CE, Gagliardi CA, Gangadharan DR, Garand D, Geurts F, Gibson A, Girard M, Gliske S, Grosnick D, Guo Y, Gupta A, Gupta S, Guryn W, Haag B, Hajkova O, Hamed A, Han LX, Haque R, Harris JW, Hays-Wehle JP, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang B, Huang HZ, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Kesich A, Khan ZH, Kikola DP, Kisel I, Kisiel A, Koetke DD, Kollegger T, Konzer J, Koralt I, Korsch W, Kotchenda L, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Leight W, LeVine MJ, Li C, Li W, Li X, Li X, Li Y, Li ZM, Lima LM, Lisa MA, Liu F, Ljubicic T, Llope WJ, Longacre RS, Luo X, Ma GL, Ma YG, Madagodagettige Don DMMD, Mahapatra DP, Majka R, Margetis S, Markert C, Masui H, Matis HS, McDonald D, McShane TS, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Morozov DA, Munhoz MG, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nelson JM, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Ohlson A, Okorokov V, Oldag EW, Oliveira RAN, Pachr M, Page BS, Pal SK, Pan YX, Pandit Y, Panebratsev Y, Pawlak T, Pawlik B, Pei H, Perkins C, Peryt W, Peterson A, Pile P, Planinic M, Pluta J, Plyku D, Poljak N, Porter J, Poskanzer AM, Pruthi NK, Przybycien M, Pujahari PR, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Riley CK, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ross JF, Roy A, Ruan L, Rusnak J, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandacz A, Sandweiss J, Sangaline E, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Singaraju RN, Skoby MJ, Smirnov D, Smirnov N, Solanki D, Sorensen P, deSouza UG, Spinka HM, Srivastava B, Stanislaus TDS, Stevens JR, Stock R, Strikhanov M, Stringfellow B, Suaide AAP, Sumbera M, Sun X, Sun XM, Sun Y, Sun Z, Surrow B, Svirida DN, Symons TJM, Szanto de Toledo A, Takahashi J, Tang AH, Tang Z, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Trzeciak BA, Tsai OD, Turnau J, Ullrich T, Underwood DG, Van Buren G, van Nieuwenhuizen G, Vanfossen JA, Varma R, Vasconcelos GMS, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Voloshin SA, Vossen A, Wada M, Walker M, Wang F, Wang G, Wang H, Wang JS, Wang XL, Wang Y, Wang Y, Webb G, Webb JC, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Xiao Z, Xie W, Xin K, Xu H, Xu N, Xu QH, Xu Y, Xu Z, Yan W, Yang C, Yang Y, Yang Y, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Zawisza Y, Zbroszczyk H, Zha W, Zhang JB, Zhang S, Zhang XP, Zhang Y, Zhang ZP, Zhao F, Zhao J, Zhong C, Zhu X, Zhu YH, Zoulkarneeva Y, Zyzak M. Energy dependence of moments of net-proton multiplicity distributions at RHIC. Phys Rev Lett 2014; 112:032302. [PMID: 24484135 DOI: 10.1103/physrevlett.112.032302] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Indexed: 06/03/2023]
Abstract
We report the beam energy (sqrt[sNN]=7.7-200 GeV) and collision centrality dependence of the mean (M), standard deviation (σ), skewness (S), and kurtosis (κ) of the net-proton multiplicity distributions in Au+Au collisions. The measurements are carried out by the STAR experiment at midrapidity (|y|<0.5) and within the transverse momentum range 0.4<pT<0.8 GeV/c in the first phase of the Beam Energy Scan program at the Relativistic Heavy Ion Collider. These measurements are important for understanding the quantum chromodynamic phase diagram. The products of the moments, Sσ and κσ2, are sensitive to the correlation length of the hot and dense medium created in the collisions and are related to the ratios of baryon number susceptibilities of corresponding orders. The products of moments are found to have values significantly below the Skellam expectation and close to expectations based on independent proton and antiproton production. The measurements are compared to a transport model calculation to understand the effect of acceptance and baryon number conservation and also to a hadron resonance gas model.
Collapse
Affiliation(s)
- L Adamczyk
- AGH University of Science and Technology, Cracow, Poland
| | - J K Adkins
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - J Alford
- Kent State University, Kent, Ohio 44242, USA
| | - C D Anson
- Ohio State University, Columbus, Ohio 43210, USA
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - D Arkhipkin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E C Aschenauer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Averichev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Balewski
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - A Banerjee
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - Z Barnovska
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - D R Beavis
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Bellwied
- University of Houston, Houston, Texas 77204, USA
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - A K Bhati
- Panjab University, Chandigarh 160014, India
| | - P Bhattarai
- University of Texas, Austin, Texas 78712, USA
| | - H Bichsel
- University of Washington, Seattle, Washington 98195, USA
| | - J Bielcik
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - J Bielcikova
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - L C Bland
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | | | - J Bouchet
- Kent State University, Kent, Ohio 44242, USA
| | - A V Brandin
- Moscow Engineering Physics Institute, Moscow, Russia
| | - S G Brovko
- University of California, Davis, California 95616, USA
| | - S Bültmann
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - I Bunzarov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - T P Burton
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | - H Caines
- Yale University, New Haven, Connecticut 06520, USA
| | | | - D Cebra
- University of California, Davis, California 95616, USA
| | - R Cendejas
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M C Cervantes
- Texas A&M University, College Station, Texas 77843, USA
| | - P Chaloupka
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - Z Chang
- Texas A&M University, College Station, Texas 77843, USA
| | | | - H F Chen
- University of Science and Technology of China, Hefei 230026, China
| | - J H Chen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Chen
- Central China Normal University (HZNU), Wuhan 430079, China
| | - J Cheng
- Tsinghua University, Beijing 100084, China
| | - M Cherney
- Creighton University, Omaha, Nebraska 68178, USA
| | - A Chikanian
- Yale University, New Haven, Connecticut 06520, USA
| | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | - R Corliss
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - J G Cramer
- University of Washington, Seattle, Washington 98195, USA
| | - H J Crawford
- University of California, Berkeley, California 94720, USA
| | - X Cui
- University of Science and Technology of China, Hefei 230026, China
| | - S Das
- Institute of Physics, Bhubaneswar 751005, India
| | | | - L C De Silva
- University of Houston, Houston, Texas 77204, USA
| | - R R Debbe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Deng
- Shandong University, Jinan, Shandong 250100, China
| | | | | | - S Dhamija
- Indiana University, Bloomington, Indiana 47408, USA
| | - B di Ruzza
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Dilks
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - F Ding
- University of California, Davis, California 95616, USA
| | - P Djawotho
- Texas A&M University, College Station, Texas 77843, USA
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J E Draper
- University of California, Davis, California 95616, USA
| | - C M Du
- Institute of Modern Physics, Lanzhou, China
| | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L G Efimov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Engelage
- University of California, Berkeley, California 94720, USA
| | - K S Engle
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - G Eppley
- Rice University, Houston, Texas 77251, USA
| | - L Eun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - S Fazio
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Fedorisin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - P Filip
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - E Finch
- Yale University, New Haven, Connecticut 06520, USA
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C E Flores
- University of California, Davis, California 95616, USA
| | - C A Gagliardi
- Texas A&M University, College Station, Texas 77843, USA
| | | | - D Garand
- Purdue University, West Lafayette, Indiana 47907, USA
| | - F Geurts
- Rice University, Houston, Texas 77251, USA
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - M Girard
- Warsaw University of Technology, Warsaw, Poland
| | - S Gliske
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - Y Guo
- University of Science and Technology of China, Hefei 230026, China
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - S Gupta
- University of Jammu, Jammu 180001, India
| | - W Guryn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Haag
- University of California, Davis, California 95616, USA
| | - O Hajkova
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - A Hamed
- Texas A&M University, College Station, Texas 77843, USA
| | - L-X Han
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - R Haque
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - J W Harris
- Yale University, New Haven, Connecticut 06520, USA
| | - J P Hays-Wehle
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - S Heppelmann
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Hirsch
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - D J Hofman
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - S Horvat
- Yale University, New Haven, Connecticut 06520, USA
| | - B Huang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H Z Huang
- University of California, Los Angeles, California 90095, USA
| | - P Huck
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T J Humanic
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Igo
- University of California, Los Angeles, California 90095, USA
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - H Jang
- Korea Institute of Science and Technology Information, Daejeon, Korea
| | - E G Judd
- University of California, Berkeley, California 94720, USA
| | | | - D Kalinkin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - K Kang
- Tsinghua University, Beijing 100084, China
| | - K Kauder
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - H W Ke
- Central China Normal University (HZNU), Wuhan 430079, China
| | - D Keane
- Kent State University, Kent, Ohio 44242, USA
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - A Kesich
- University of California, Davis, California 95616, USA
| | - Z H Khan
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - D P Kikola
- Purdue University, West Lafayette, Indiana 47907, USA
| | - I Kisel
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt, Germany
| | - A Kisiel
- Warsaw University of Technology, Warsaw, Poland
| | - D D Koetke
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - T Kollegger
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt, Germany
| | - J Konzer
- Purdue University, West Lafayette, Indiana 47907, USA
| | - I Koralt
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Korsch
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - L Kotchenda
- Moscow Engineering Physics Institute, Moscow, Russia
| | - P Kravtsov
- Moscow Engineering Physics Institute, Moscow, Russia
| | - K Krueger
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Kulakov
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt, Germany
| | - L Kumar
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - R A Kycia
- Cracow University of Technology, Cracow, Poland
| | - M A C Lamont
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K D Landry
- University of California, Los Angeles, California 90095, USA
| | - J Lauret
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Leight
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - M J LeVine
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Li
- University of Science and Technology of China, Hefei 230026, China
| | - W Li
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Li
- Purdue University, West Lafayette, Indiana 47907, USA
| | - X Li
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - Y Li
- Tsinghua University, Beijing 100084, China
| | - Z M Li
- Central China Normal University (HZNU), Wuhan 430079, China
| | - L M Lima
- Universidade de Sao Paulo, Sao Paulo, Brazil
| | - M A Lisa
- Ohio State University, Columbus, Ohio 43210, USA
| | - F Liu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W J Llope
- Rice University, Houston, Texas 77251, USA
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Luo
- Central China Normal University (HZNU), Wuhan 430079, China
| | - G L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y G Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | | | | | - R Majka
- Yale University, New Haven, Connecticut 06520, USA
| | - S Margetis
- Kent State University, Kent, Ohio 44242, USA
| | - C Markert
- University of Texas, Austin, Texas 78712, USA
| | - H Masui
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D McDonald
- Rice University, Houston, Texas 77251, USA
| | - T S McShane
- Creighton University, Omaha, Nebraska 68178, USA
| | - N G Minaev
- Institute of High Energy Physics, Protvino, Russia
| | | | - B Mohanty
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - M M Mondal
- Texas A&M University, College Station, Texas 77843, USA
| | - D A Morozov
- Institute of High Energy Physics, Protvino, Russia
| | - M G Munhoz
- Universidade de Sao Paulo, Sao Paulo, Brazil
| | - M K Mustafa
- Purdue University, West Lafayette, Indiana 47907, USA
| | - B K Nandi
- Indian Institute of Technology, Mumbai, India
| | - Md Nasim
- National Institute of Science Education and Research, Bhubaneswar 751005, India
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - J M Nelson
- University of Birmingham, Birmingham, United Kingdom
| | - L V Nogach
- Institute of High Energy Physics, Protvino, Russia
| | - S Y Noh
- Korea Institute of Science and Technology Information, Daejeon, Korea
| | - J Novak
- Michigan State University, East Lansing, Michigan 48824, USA
| | - S B Nurushev
- Institute of High Energy Physics, Protvino, Russia
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Oh
- Pusan National University, Pusan, Republic of Korea
| | - A Ohlson
- Yale University, New Haven, Connecticut 06520, USA
| | - V Okorokov
- Moscow Engineering Physics Institute, Moscow, Russia
| | - E W Oldag
- University of Texas, Austin, Texas 78712, USA
| | | | - M Pachr
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - B S Page
- Indiana University, Bloomington, Indiana 47408, USA
| | - S K Pal
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - Y X Pan
- University of California, Los Angeles, California 90095, USA
| | - Y Pandit
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - Y Panebratsev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - T Pawlak
- Warsaw University of Technology, Warsaw, Poland
| | - B Pawlik
- Institute of Nuclear Physics PAN, Cracow, Poland
| | - H Pei
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Perkins
- University of California, Berkeley, California 94720, USA
| | - W Peryt
- Warsaw University of Technology, Warsaw, Poland
| | - A Peterson
- Ohio State University, Columbus, Ohio 43210, USA
| | - P Pile
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Planinic
- University of Zagreb, Zagreb, HR-10002, Croatia
| | - J Pluta
- Warsaw University of Technology, Warsaw, Poland
| | - D Plyku
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N Poljak
- University of Zagreb, Zagreb, HR-10002, Croatia
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A M Poskanzer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N K Pruthi
- Panjab University, Chandigarh 160014, India
| | - M Przybycien
- AGH University of Science and Technology, Cracow, Poland
| | | | - J Putschke
- Wayne State University, Detroit, Michigan 48201, USA
| | - H Qiu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Quintero
- Kent State University, Kent, Ohio 44242, USA
| | - S Ramachandran
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - R Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - S Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R L Ray
- University of Texas, Austin, Texas 78712, USA
| | - C K Riley
- Yale University, New Haven, Connecticut 06520, USA
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | - J L Romero
- University of California, Davis, California 95616, USA
| | - J F Ross
- Creighton University, Omaha, Nebraska 68178, USA
| | - A Roy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Rusnak
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - N R Sahoo
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - P K Sahu
- Institute of Physics, Bhubaneswar 751005, India
| | - I Sakrejda
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Salur
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Sandacz
- Warsaw University of Technology, Warsaw, Poland
| | - J Sandweiss
- Yale University, New Haven, Connecticut 06520, USA
| | - E Sangaline
- University of California, Davis, California 95616, USA
| | - A Sarkar
- Indian Institute of Technology, Mumbai, India
| | - J Schambach
- University of Texas, Austin, Texas 78712, USA
| | | | - A M Schmah
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Schmitz
- Max-Planck-Institut für Physik, Munich, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178, USA
| | - P Seyboth
- Max-Planck-Institut für Physik, Munich, Germany
| | - N Shah
- University of California, Los Angeles, California 90095, USA
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - M Shao
- University of Science and Technology of China, Hefei 230026, China
| | - B Sharma
- Panjab University, Chandigarh 160014, India
| | - W Q Shen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S S Shi
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Q Y Shou
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E P Sichtermann
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R N Singaraju
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - M J Skoby
- Indiana University, Bloomington, Indiana 47408, USA
| | - D Smirnov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Smirnov
- Yale University, New Haven, Connecticut 06520, USA
| | - D Solanki
- University of Rajasthan, Jaipur 302004, India
| | - P Sorensen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - U G deSouza
- Universidade de Sao Paulo, Sao Paulo, Brazil
| | - H M Spinka
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - J R Stevens
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - R Stock
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt, Germany
| | - M Strikhanov
- Moscow Engineering Physics Institute, Moscow, Russia
| | | | | | - M Sumbera
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - X Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - X M Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Y Sun
- University of Science and Technology of China, Hefei 230026, China
| | - Z Sun
- Institute of Modern Physics, Lanzhou, China
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - T J M Symons
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J Takahashi
- Universidade Estadual de Campinas, Sao Paulo, Brazil
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Tang
- University of Science and Technology of China, Hefei 230026, China
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824, USA
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Timmins
- University of Houston, Houston, Texas 77204, USA
| | - D Tlusty
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S Trentalange
- University of California, Los Angeles, California 90095, USA
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843, USA
| | - P Tribedy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | | | - O D Tsai
- University of California, Los Angeles, California 90095, USA
| | - J Turnau
- Institute of Nuclear Physics PAN, Cracow, Poland
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G van Nieuwenhuizen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | | | - R Varma
- Indian Institute of Technology, Mumbai, India
| | | | - A N Vasiliev
- Institute of High Energy Physics, Protvino, Russia
| | - R Vertesi
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y P Viyogi
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S A Voloshin
- Wayne State University, Detroit, Michigan 48201, USA
| | - A Vossen
- Indiana University, Bloomington, Indiana 47408, USA
| | - M Wada
- University of Texas, Austin, Texas 78712, USA
| | - M Walker
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA
| | - F Wang
- Purdue University, West Lafayette, Indiana 47907, USA
| | - G Wang
- University of California, Los Angeles, California 90095, USA
| | - H Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J S Wang
- Institute of Modern Physics, Lanzhou, China
| | - X L Wang
- University of Science and Technology of China, Hefei 230026, China
| | - Y Wang
- Tsinghua University, Beijing 100084, China
| | - Y Wang
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - G Webb
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824, USA
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408, USA
| | - R Witt
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - Y F Wu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z Xiao
- Tsinghua University, Beijing 100084, China
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Xin
- Rice University, Houston, Texas 77251, USA
| | - H Xu
- Institute of Modern Physics, Lanzhou, China
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Q H Xu
- Shandong University, Jinan, Shandong 250100, China
| | - Y Xu
- University of Science and Technology of China, Hefei 230026, China
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Yan
- Tsinghua University, Beijing 100084, China
| | - C Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Y Yang
- Institute of Modern Physics, Lanzhou, China
| | - Y Yang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - P Yepes
- Rice University, Houston, Texas 77251, USA
| | - L Yi
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I-K Yoo
- Pusan National University, Pusan, Republic of Korea
| | - Y Zawisza
- University of Science and Technology of China, Hefei 230026, China
| | | | - W Zha
- University of Science and Technology of China, Hefei 230026, China
| | - J B Zhang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - S Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X P Zhang
- Tsinghua University, Beijing 100084, China
| | - Y Zhang
- University of Science and Technology of China, Hefei 230026, China
| | - Z P Zhang
- University of Science and Technology of China, Hefei 230026, China
| | - F Zhao
- University of California, Los Angeles, California 90095, USA
| | - J Zhao
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - C Zhong
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Zhu
- Tsinghua University, Beijing 100084, China
| | - Y H Zhu
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y Zoulkarneeva
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt, Germany
| |
Collapse
|
36
|
Adamczyk L, Adkins J, Agakishiev G, Aggarwal M, Ahammed Z, Alekseev I, Alford J, Anson C, Aparin A, Arkhipkin D, Aschenauer E, Averichev G, Balewski J, Banerjee A, Barber B, Barnovska Z, Beavis D, Bellwied R, Betancourt M, Bhasin A, Bhati A, Bhattarai P, Bichsel H, Bielcik J, Bielcikova J, Bland L, Bordyuzhin I, Borowski W, Bouchet J, Brandin A, Bridgeman A, Brovko S, Bültmann S, Bunzarov I, Burton T, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Cendejas R, Cervantes M, Chaloupka P, Chang Z, Chattopadhyay S, Chen H, Chen J, Chen L, Cheng J, Cherney M, Chikanian A, Christie W, Chwastowski J, Codrington M, Corliss R, Cramer J, Crawford H, Cui X, Das S, Davila Leyva A, De Silva L, Debbe R, Dedovich T, Deng J, Derevschikov A, Derradi de Souza R, Dhamija S, di Ruzza B, Didenko L, Dilks C, Ding F, Dion A, Djawotho P, Dong X, Drachenberg J, Draper J, Du C, Dunkelberger L, Dunlop J, Efimov L, Engelage J, Engle K, Eppley G, Eun L, Evdokimov O, Fatemi R, Fazio S, Fedorisin J, Fersch R, Filip P, Finch E, Fisyak Y, Flores C, Gagliardi C, Gangadharan D, Garand D, Geurts F, Gibson A, Girard M, Gliske S, Grosnick D, Guo Y, Gupta A, Gupta S, Guryn W, Haag B, Hajkova O, Hamed A, Han LX, Haque R, Harris J, Hays-Wehle J, He W, Heppelmann S, Hirsch A, Hoffmann G, Hofman D, Horvat S, Huang B, Huang H, Huck P, Humanic T, Igo G, Jacobs W, Jang H, Jena C, Judd E, Kabana S, Kalinkin D, Kang K, Kauder K, Ke H, Keane D, Kechechyan A, Kesich A, Khan Z, Kikola D, Kisel I, Kisiel A, Koetke D, Kollegger T, Konzer J, Koralt I, Korsch W, Kotchenda L, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia R, Lamont M, Landgraf J, Landry K, Lauret J, Lebedev A, Lednicky R, Lee J, Leight W, LeVine M, Li C, Li W, Li X, Li X, Li Y, Li Z, Lima L, Lisa M, Liu F, Ljubicic T, Llope W, Longacre R, Luo X, Ma G, Ma Y, Madagodagettige Don D, Mahapatra D, Majka R, Manweiler R, Margetis S, Markert C, Masui H, Matis H, McDonald D, McShane T, Minaev N, Mioduszewski S, Mohanty B, Mondal M, Morozov D, Munhoz M, Mustafa M, Naglis M, Nandi B, Nasim M, Nayak T, Nelson J, Nogach L, Noh S, Nord P, Novak J, Nurushev S, Odyniec G, Ogawa A, Oh K, Ohlson A, Okorokov V, Oldag E, Oliveira R, Olson D, Pachr M, Page B, Pal S, Pan Y, Pandit Y, Panebratsev Y, Pawlak T, Pawlik B, Pei H, Perkins C, Peryt W, Peterson A, Pile P, Planinic M, Pluta J, Plyku D, Pochron W, Poljak N, Porter J, Poskanzer A, Powell C, Pruneau C, Pruthi N, Przybycien M, Pujahari P, Putschke J, Qiu H, Ramachandran S, Raniwala R, Raniwala S, Ray R, Riley C, Ritter H, Roberts J, Rogachevskiy O, Romero J, Ross J, Roy A, Ruan L, Rusnak J, Sahoo N, Sahu P, Sakrejda I, Salur S, Sandacz A, Sandweiss J, Sangaline E, Sarkar A, Schambach J, Scharenberg R, Schaub J, Schmah A, Schmidke W, Schmitz N, Seger J, Selyuzhenkov I, Seyboth P, Shah N, Shahaliev E, Shanmuganathan P, Shao M, Sharma B, Shen W, Shi S, Shou Q, Sichtermann E, Singaraju R, Skoby M, Smirnov D, Smirnov N, Solanki D, Sorensen P, deSouza U, Spinka H, Srivastava B, Stanislaus T, Stevens J, Stock R, Strikhanov M, Stringfellow B, Suaide A, Sumbera M, Sun X, Sun X, Sun Y, Sun Z, Surrow B, Svirida D, Symons T, Szanto de Toledo A, Takahashi J, Tang A, Tang Z, Tarnowsky T, Thomas J, Timmins A, Tlusty D, Tokarev M, Trentalange S, Tribble R, Tribedy P, Trzeciak B, Tsai O, Turnau J, Ullrich T, Underwood D, Van Buren G, van Nieuwenhuizen G, Vanfossen J, Varma R, Vasconcelos G, Vasiliev A, Vertesi R, Videbæk F, Viyogi Y, Vokal S, Voloshin S, Vossen A, Wada M, Walker M, Wang F, Wang G, Wang H, Wang J, Wang Q, Wang X, Wang Y, Wang Y, Webb G, Webb J, Westfall G, Wieman H, Wissink S, Witt R, Wu Y, Xiao Z, Xie W, Xin K, Xu H, Xu N, Xu Q, Xu W, Xu Y, Xu Z, Yan W, Yang C, Yang Y, Yang Y, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Zawisza Y, Zbroszczyk H, Zha W, Zhang J, Zhang S, Zhang X, Zhang Y, Zhang Z, Zhao F, Zhao J, Zhong C, Zhu X, Zhu Y, Zoulkarneeva Y, Zyzak M. Neutral pion cross section and spin asymmetries at intermediate pseudorapidity in polarized proton collisions ats=200 GeV. Int J Clin Exp Med 2014. [DOI: 10.1103/physrevd.89.012001] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
37
|
Shah BK, Hewett Y, Peterson A, Tretheway D. Resolution of granuloma annulare following treatment with bendamustine and rituximab in a patient with follicular lymphoma: A serendipitous finding. J Postgrad Med 2014; 60:406-8. [DOI: 10.4103/0022-3859.143975] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
38
|
Al-Nakkash L, Janjulia T, Peterson K, Lucy D, Wilson D, Peterson A, Prozialeck W, Broderick TL. Genistein and exercise do not improve cardiovascular risk factors in the ovariectomized rat. Climacteric 2013; 17:136-47. [PMID: 23679226 DOI: 10.3109/13697137.2013.804503] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To investigate the effect of either genistein, or exercise, or both, on parameters that are indicators of cardiovascular health. METHODS We investigated the effect of genistein treatment (300 mg genisten/kg body weight/day), or exercise training, or combined genistein and exercise training, for a period of 6 weeks on physical characteristics, cardiovascular plasma markers, blood pressure, aortic morphology, cardiac structure and oxidative stress in the ovariectomized (OVX) Sprague-Dawley rat. Comparisons were made with intact rats. RESULTS Ovariectomy (compared to intact) resulted in significant decreases in uterine weight (6-fold, p < 0.0001), insulin levels (4-fold, p = 0.0214), insulin/glucose ratio (3-fold, p = 0.0029), and tumor necrosis factor-α plasma levels (2-fold, p < 0.0001). Similarly, aortic blood pressure was significantly increased (by 8%, p < 0.0033) in OVX rats, without changes in aortic luminal or wall dimensions. Heart surface area was significantly increased (by 16%, p = 0.0160) in OVX rats and this was without changes in non-protein thiol levels (a marker of oxidative stress). Physical characteristics were not altered by treatment with genistein, or genistein with exercise, with the exception of increased uterine weight in OVX rats treated under these same conditions. There were no effects of genistein or exercise on indices of blood pressure and aortic morphology in the OVX rat. However, right ventricular nuclei count was reduced in sedentary genistein-treated rats compared to non-treated control OVX rats. CONCLUSION Our results indicate that administration of genistein at this dose, treadmill running, or the combination of both, are not associated with any improvement in cardiovascular function and structure, and risk factors in an ovariectomy model of postmenopause.
Collapse
Affiliation(s)
- L Al-Nakkash
- * Department of Physiology, Midwestern University, Arizona College of Osteopathic Medicine , Glendale, AZ
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Peterson A, Mattek N, Clemons A, Bowman GL, Buracchio T, Kaye J, Quinn J. Serum vitamin D concentrations are associated with falling and cognitive function in older adults. J Nutr Health Aging 2012; 16:898-901. [PMID: 23208029 PMCID: PMC3593063 DOI: 10.1007/s12603-012-0378-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OBJECTIVES To elucidate the mechanism through which vitamin D is associated with decreased falls. DESIGN This was a convenience sample from a larger observational study examining correlations between vitamin D and 1) falls, 2) motor function, and 3) cognition (n=159). SETTING Falls data were collected via weekly on-line surveys completed in the participants' homes. Yearly evaluations of motor and cognitive function were conducted in an out-patient setting of a large tertiary medical center. PARTICIPANTS Participants from the Intelligent Systems for Assessment of Aging Changes Study (ISAAC), a community-based cohort study of independently living older adults over age 70, who had vitamin D concentration within 6 months of clinical evaluations were included in the analysis. RESULTS Participants mean age was 85 years and 74% were women. Fallers (n=37) had significantly lower vitamin D concentration (32.9ng/ml) compared to non-fallers (39.2ng/ml) (p<0.01). The relationship between vitamin D and falls remained significant after adjusting for age, health status (via CIRS), and supplement use (p=0.004). Vitamin D concentration were significantly associated with cognitive impairment (Clinical Dementia Rating = 0.5) (p=0.02) and MMSE (p<0.01) after adjusting for age, gender, and education. Vitamin D concentrations did not correlate with any motor measures. CONCLUSION Vitamin D concentrations correlated with cognition and falls, but not with motor measures. Further research is needed to demonstrate a causal relationship between vitamin D and cognitive function and determine if cognition plays a role in falls reduction.
Collapse
Affiliation(s)
- A Peterson
- Department of Neurology, Oregon Health and Science University and Portland Veteran Affairs Medical Center, Portland, OR 97239 USA.
| | | | | | | | | | | | | |
Collapse
|
40
|
Fayolle G, Levick W, Lajiness-O'Neill R, Fastenau P, Briskin S, Bass N, Silva M, Critchfield E, Nakase-Richardson R, Hertza J, Loughan A, Perna R, Northington S, Boyd S, Anderson A, Peery S, Chafetz M, Maris M, Ramezani A, Sylvester C, Goldberg K, Constantinou M, Karekla M, Hall J, Edwards M, Balldin V, Strutt A, Pavlik V, Marquez de la Plata C, Cullum M, lacritz L, Reisch J, Massman P, Royall D, Barber R, Younes S, Wiechmann A, O'Bryant S, Patel K, Suhr J, Patel K, Suhr J, Chari S, Yokoyama J, Bettcher B, Karydas A, Miller B, Kramer J, Zec R, Fritz S, Kohlrus S, Robbs R, Ala T, Gifford K, Cantwell N, Romano R, Jefferson A, Holland A, Newton S, Bunting J, Coe M, Carmona J, Harrison D, Puente A, Terry D, Faraco C, Brown C, Patel A, Watts A, Kent A, Siegel J, Miller S, Ernst W, Chelune G, Holdnack J, Sheehan J, Duff K, Pedraza O, Crawford J, Terry D, Puente A, Brown C, Faraco C, Watts A, Patel A, Kent A, Siegel J, Miller L, Younes S, Hobson Balldin V, Benavides H, Johnson L, Hall J, Tshuma L, O'Bryant S, Dezhkam N, Hayes L, Love C, Stephens B, Webbe F, Allen C, Lemann E, Davis A, Pierson E, Lutz J, Piehl J, Holler K, Kavanaugh B, Tayim F, Llanes S, Mulligan K, Poston K, Riccio C, Beathard J, Cohen M, Stolberg P, Hart J, Jones W, Mayfield J, Allen D, Weller J, Dunham K, Demireva P, McInerney K, Suhr J, Dykstra J, Riddle T, Suhr J, Primus M, Riccio C, Highsmith J, Everhart D, Shadi S, Lehockey K, Sullivan S, Lucas M, Mandava S, Murphy B, Donovick P, Lalwani L, Rosselli M, Coad S, Carrasco R, Sofko C, Scarisbrick D, Golden C, Coad S, Zuckerman S, Golden C, Perna R, Loughan A, Hertza J, Brand J, Rivera Mindt M, Denney R, Schaffer S, Alper K, Devinsky O, Barr W, Langer K, Fraiman J, Scagliola J, Roman E, Martinez A, Cohen M, Dunham K, Riccio C, Martin P, Robbins J, Golden C, Axelrod B, Etherton J, Konopacki K, Moses J, Juliano A, Whiteside D, Rolin S, Widmann G, Franzwa M, Sokal B, Mark V, Doyle K, Morgan E, Weber E, Bondi M, Delano-Wood L, Grant I, Sibson J, Woods S, Andrews P, McGregor S, Golden C, Etherton J, Allen C, Cormier R, Cumley N, Elek M, Green M, Ogbeide S, Kruger A, Pacheco L, Robinson G, Welch H, Etherton J, Allen C, Cormier R, Cumley N, Kruger A, Pacheco L, Glover M, Parriott D, Jones W, Loe S, Hughes L, Natta L, Moses J, Vincent A, Roebuck-Spencer T, Bryan C, Padua M, Denney R, Moses J, Quenicka W, McGoldirck K, Bennett T, Soper H, Collier S, Connolly M, Hanratty A, Di Pinto M, Magnuson S, Dunham K, Handel E, Davidson K, Livers E, Frantz S, Allen J, Jerard T, Moses J, Pierce S, Sakhai S, Newton S, Warchol A, Holland A, Bunting J, Coe M, Carmona J, Harrison D, Barney S, Thaler N, Sutton G, Strauss G, Allen D, Hunter B, Bennett T, Quenicka W, McGoldrick K, Soper H, Sordahl J, Torrence N, John S, Gavett B, O'Bryant S, Shadi S, Denney R, Nichols C, Riccio C, Cohen M, Dennison A, Wasserman T, Schleicher-Dilks S, Adler M, Golden C, Olivier T, Schleicher-Dilks S, Golden C, LeMonda B, McGinley J, Pritchett A, Chang L, Cloak C, Cunningham E, Lohaugen G, Skranes J, Ernst T, Parke E, Thaler N, Etcoff L, Allen D, Andrews P, McGregor S, Golden C, Northington S, Daniels R, Loughan A, Perna R, Hertza J, Hochsztein N, Miles-Mason E, Granader Y, Vasserman M, MacAllister W, Casto B, Peery S, Patrick K, Hurewitz F, Chute D, Booth A, Koch C, Roid G, Balkema N, Kiefel J, Bell L, Maerlender A, Belkin T, Katzenstein J, Semerjian C, Culotta V, Band E, Yosick R, Burns T, Arenivas A, Bearden D, Olson K, Jacobson K, Ubogy S, Sterling C, Taub E, Griffin A, Rickards T, Uswatte G, Davis D, Sweeney K, Llorente A, Boettcher A, Hill B, Ploetz D, Kline J, Rohling M, O'Jile J, Holler K, Petrauskas V, Long J, Casey J, Long J, Petrauskas V, Duda T, Hodsman S, Casey J, Stricker S, Martner S, Hansen R, Ferraro F, Tangen R, Hanratty A, Tanabe M, O'Callaghan E, Houskamp B, McDonald L, Pick L, Guardino D, Pick L, Pietz T, Kayser K, Gray R, Letteri A, Crisologo A, Witkin G, Sanders J, Mrazik M, Harley A, Phoong M, Melville T, La D, Gomez R, Berthelson L, Robbins J, Lane E, Golden C, Rahman P, Konopka L, Fasfous A, Zink D, Peralta-Ramirez N, Perez-Garcia M, Puente A, Su S, Lin G, Kiely T, Gomez R, Schatzberg A, Keller J, Dykstra J, Suhr J, Feigon M, Renteria L, Fong M, Piper L, Lee E, Vordenberg J, Contardo C, Magnuson S, Doninger N, Luton L, Balkema N, Drane D, Phelan A, Stricker W, Poreh A, Wolkenberg F, Spira J, Lin G, Su S, Kiely T, Gomez R, Schatzberg A, Keller J, DeRight J, Jorgensen R, Fitzpatrick L, Crowe S, Woods S, Doyle K, Weber E, Cameron M, Cattie J, Cushman C, Grant I, Blackstone K, Woods S, Weber E, Grant I, Moore D, Roberg B, Somogie M, Thelen J, Lovelace C, Bruce J, Gerstenecker A, Mast B, Litvan I, Hargrave D, Schroeder R, Buddin W, Baade L, Heinrichs R, Thelen J, Roberg B, Somogie M, Lovelace C, Bruce J, Boseck J, Berry K, Koehn E, Davis A, Meyer B, Gelder B, Sussman Z, Espe-Pfeifer P, Musso M, Barker A, Jones G, Gouvier W, Weber E, Woods S, Grant I, Johnson V, Zaytsev L, Freier-Randall M, Sutton G, Thaler N, Ringdahl E, Allen D, Olsen J, Byrd D, Rivera-Mindt M, Fellows R, Morgello S, Wheaton V, Jaehnert S, Ellis C, Olavarria H, Loftis J, Huckans M, Pimental P, Frawley J, Welch M, Jennette K, Rinehardt E, Schoenberg M, Strober L, Genova H, Wylie G, DeLuca J, Chiaravalloti N, Hertza J, Loughan A, Perna R, Northington S, Boyd S, Hertza J, Loughan A, Perna R, Northington S, Boyd S, Ibrahim E, Seiam A, Ibrahim E, Bohlega S, Rinehardt E, Lloyd H, Goldberg M, Marceaux J, Fallows R, McCoy K, Yehyawi N, Luther E, Hilsabeck R, Fulton R, Stevens P, Erickson S, Dodzik P, Williams R, Dsurney J, Najafizadeh L, McGovern J, Chowdhry F, Acevedo A, Bakhtiar A, Karamzadeh N, Amyot F, Gandjbakhche A, Haddad M, Taub E, Johnson M, Wade J, Harper L, Rickards T, Sterling C, Barghi A, Uswatte G, Mark V, Balkema N, Christopher G, Marcus D, Spady M, Bloom J, Wiechmann A, Hall J, Loughan A, Perna R, Hertza J, Northington S, Zimmer A, Webbe F, Miller M, Schuster D, Ebner H, Mortimer B, Webbe F, Palmer G, Happe M, Paxson J, Jurek B, Graca J, Meyers J, Lange R, Brickell T, French L, Lange R, Iverson G, Shewchuk J, Madler B, Heran M, Brubacher J, Brickell T, Lange R, Ivins B, French L, Baldassarre M, Paper T, Herrold A, Chin A, Zgaljardic D, Oden K, Lambert M, Dickson S, Miller R, Plenger P, Jacobson K, Olson K, Sutherland E, Glatts C, Schatz P, Walker K, Philip N, McClaughlin S, Mooney S, Seats E, Carnell V, Raintree J, Brown D, Hodges C, Amerson E, Kennedy C, Moore J, Schatz P, Ferris C, Roebuck-Spencer T, Vincent A, Bryan C, Catalano D, Warren A, Monden K, Driver S, Chau P, Seegmiller R, Baker M, Malach S, Mintz J, Villarreal R, Peterson A, Leininger S, Strong C, Donders J, Merritt V, Vargas G, Rabinowitz A, Arnett P, Whipple E, Schultheis M, Robinson K, Iacovone D, Biester R, Alfano D, Nicholls M, Vargas G, Rabinowitz A, Arnett P, Rabinowitz A, Vargas G, Arnett P, Klas P, Jeffay E, Zakzanis K, Vandermeer M, Jeffay E, Zakzanis K, Womble M, Rohling M, Hill B, Corley E, Considine C, Fichtenberg N, Harrison J, Pollock M, Mouanoutoua A, Brimager A, Lebby P, Sullivan K, Edmed S, Silva M, Nakase-Richardson R, Critchfield E, Kieffer K, McCarthy M, Wiegand L, Lindsey H, Hernandez M, Puente A, Noniyeva Y, Lapis Y, Padua M, Poole J, Brooks B, McKay C, Mrazik M, Meeuwisse W, Emery C, Brooks B, Mazur-Mosiewicz A, Sherman E, Brooks B, Mazur-Mosiewicz A, Kirkwood M, Sherman E, Gunner J, Miele A, Silk-Eglit G, Lynch J, McCaffrey R, Stewart J, Tsou J, Scarisbrick D, Chan R, Bure-Reyes A, Cortes L, Gindy S, Golden C, Hunter B, Biddle C, Shah D, Jaberg P, Moss R, Horner M, VanKirk K, Dismuke C, Turner T, Muzzy W, Dunnam M, Miele A, Warner G, Donnelly K, Donnelly J, Kittleson J, Bradshaw C, Alt M, Margolis S, Ostroy E, Rolin S, Higgins K, Denney R, Rolin S, Eng K, Biddle C, Akeson S, Wall J, Davis J, Hansel J, Hill B, Rohling M, Wang B, Womble M, Gervais R, Greiffenstein M, Denning J, Denning J, Schroeder R, Buddin W, Hargrave D, VonDran E, Campbell E, Brockman C, Heinrichs R, Baade L, Buddin W, Hargrave D, Schroeder R, Teichner G, Waid R, Buddin W, Schroeder R, Teichner G, Waid R, Buican B, Armistead-Jehle P, Bailie J, Dilay A, Cottingham M, Boyd C, Asmussen S, Neff J, Schalk S, Jensen L, DenBoer J, Hall S, DenBoer J, Schalk S, Jensen L, Hall S, Miele A, Lynch J, McCaffrey R, Holcomb E, Axelrod B, Demakis G, Rimland C, Ward J, Ross M, Bailey M, Stubblefield A, Smigielski J, Geske J, Karpyak V, Reese C, Larrabee G, Suhr J, Silk-Eglit G, Gunner J, Miele A, Lynch J, McCaffrey R, Allen L, Celinski M, Gilman J, Davis J, Wall J, LaDuke C, DeMatteo D, Heilbrun K, Swirsky-Sacchetti T, Lindsey H, Puente A, Dedman A, Withers K, Chafetz M, Deneen T, Denney R, Fisher J, Spray B, Savage R, Wiener H, Tyer J, Ningaonkar V, Devlin B, Go R, Sharma V, Tsou J, Golden C, Fontanetta R, Calderon C, Coad S, Golden C, Calderon C, Fontaneta R, Coad S, Golden C, Ringdahl E, Thaler N, Sutton G, Vertinski M, Allen D, Verbiest R, Thaler N, Snyder J, Kinney J, Allen D, Rach A, Young J, Crouse E, Schretlen D, Weaver J, Buchholz A, Gordon B, Macciocchi S, Seel R, Godsall R, Brotsky J, DiRocco A, Houghton-Faryna E, Bolinger E, Hollenbeck C, Hart J, Thaler N, Vertinski M, Ringdahl E, Allen D, Lee B, Strauss G, Adams J, Martins D, Catalano L, Waltz J, Gold J, Haas G, Brown L, Luther J, Goldstein G, Kiely T, Kelley E, Lin G, Su S, Raba C, Gomez R, Trettin L, Solvason H, Schatzberg A, Keller J, Vertinski M, Thaler N, Allen D, Gold J, Buchanan R, Strauss G, Baldock D, Ringdahl E, Sutton G, Thaler N, Allen D, Fallows R, Marceaux J, McCoy K, Yehyawi N, Luther E, Hilsabeck R, Etherton J, Phelps T, Richmond S, Tapscott B, Thomlinson S, Cordeiro L, Wilkening G, Parikh M, Graham L, Grosch M, Hynan L, Weiner M, Cullum C, Hobson Balldin V, Menon C, Younes S, Hall J, Strutt A, Pavlik V, Marquez de la Plata C, Cullum M, Lacritz L, Reisch J, Massman P, Royall D, Barber R, O'Bryant S, Castro-Couch M, Irani F, Houshyarnejad A, Norman M, Peery S, Fonseca F, Bure-Reyes A, Browne B, Alvarez J, Jiminez Y, Baez V, Cortes L, Golden C, Fonseca F, Bure-Reyes A, Coad S, Alvarez J, Browne B, Baez V, Golden C, Resendiz C, Scott B, Farias G, York M, Lozano V, Mahoney M, Strutt A, Hernandez Mejia M, Puente A, Bure-Reyes A, Fonseca F, Baez V, Alvarez J, Browne B, Coad S, Jiminez Y, Cortes L, Golden C, Bure-Reyes A, Pacheco E, Homs A, Acevedo A, Ownby R, Nici J, Hom J, Lutz J, Dean R, Finch H, Pierce S, Moses J, Mann S, Feinberg J, Choi A, Kaminetskaya M, Pierce C, Zacharewicz M, Axelrod B, Gavett B, Horwitz J, Edwards M, O'Bryant S, Ory J, Gouvier W, Carbuccia K, Ory J, Carbuccia K, Gouvier W, Morra L, Garcon S, Lucas M, Donovick P, Whearty K, Campbell K, Camlic S, Donovick P, Edwards M, Balldin V, Hall J, Strutt A, Pavlik V, Marquez de la Plata C, Cullum C, Lacritz L, Reisch J, Massman P, Barber R, Royall D, Younes S, O'Bryant S, Brinckman D, Schultheis M, Ehrhart L, Weisser V, Medaglia J, Merzagora A, Reckess G, Ho T, Testa S, Gordon B, Schretlen D, Woolery H, Farcello C, Klimas N, Thaler N, Allen D, Meyer J, Vargas G, Rabinowitz A, Barwick F, Arnett P, Womble M, Rohling M, Hill B, Corley E, Drayer K, Rohling M, Ploetz D, Womble M, Hill B, Baldock D, Ringdahl E, Sutton G, Thaler N, Allen D, Galusha J, Schmitt A, Livingston R, Stewart R, Quarles L, Pagitt M, Barke C, Baker A, Baker N, Cook N, Ahern D, Correia S, Resnik L, Barnabe K, Gnepp D, Benjamin M, Zlatar Z, Garcia A, Harnish S, Crosson B, Rickards T, Mark V, Taub E, Sterling C, Vaughan L, Uswatte G, Fedio A, Sexton J, Cummings S, Logemann A, Lassiter N, Fedio P, Gremillion A, Nemeth D, Whittington T, Hansen R, Reckow J, Ferraro F, Lewandowski C, Cole J, Lewandowski A, Spector J, Ford-Johnson L, Lengenfelder J, Genova H, Sumowski J, DeLuca J, Chiaravalloti N, Loughan A, Perna R, Hertza J, Morse C, McKeever J, Zhao L, Leist T, Schultheis M, Marcinak J, Piecora K, Al-Khalil K, Webbe F, Mulligan K, Robbins J, Berthelson L, Martin P, Golden C, Piecora K, Marcinak J, Al-Khalil K, Webbe F, Mulligan K, Stewart J, Acevedo A, Ownby R, Thompson L, Kowalczyk W, Golub S, Davis A, Lemann E, Piehl J, Rita N, Moss L, Davis A, Boseck J, Berry K, Koehn E, Meyer B, Gelder B, Davis A, Nogin R, Moss L, Drapeau C, Malm S, Davis A, Lemann E, Koehn E, Drapeau C, Malm S, Boseck J, Armstrong L, Glidewell R, Orr W, Mears G. Grand Rounds. Arch Clin Neuropsychol 2012. [DOI: 10.1093/arclin/acs070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
41
|
Ramos JE, Al-Nakkash L, Peterson A, Gump BS, Janjulia T, Moore MS, Broderick TL, Carroll CC. The soy isoflavone genistein inhibits the reduction in Achilles tendon collagen content induced by ovariectomy in rats. Scand J Med Sci Sports 2012; 22:e108-14. [PMID: 22852581 DOI: 10.1111/j.1600-0838.2012.01516.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2012] [Indexed: 11/27/2022]
Abstract
The objective of this study was to evaluate the effects of genistein and moderate intensity exercise on Achilles tendon collagen and cross-linking in intact and ovariectomized (OVX) female Sprague-Dawley rats. Rats were separated into eight groups (n = 9/group): intact or OVX, treadmill exercised or sedentary, genistein-treated (300 mg/kg/day) or vehicle. After 6 weeks, tendons were assayed for the collagen-specific amino acid hydroxyproline and hydroxylyslpyridinoline (HP). Collagen content was not influenced by exercise (P = 0.40) but was lower (P < 0.001) in OVX-vehicle rats compared with intact vehicle rats (OVX: 894 ± 35 μg collagen/mg dry weight; intact: 1185 ± 72 μg collagen/mg dry weight). In contrast, collagen content in OVX rats treated with genistein was greater (P = 0.010, 1198 ± 121 μg collagen/mg dry weight) when compared with untreated rats and was not different from intact rats (P = 0.89). HP content was lower in OVX genistein-treated rats when compared with intact genistein-treated rats, but only within the sedentary animals (P = 0.05, intact-treated: 232 ± 39 mmol/mol collagen; OVX-treated: 144 ± 21 mmol/mol collagen). Our findings suggest that ovariectomy leads to a reduction in tendon collagen, which is prevented by genistein. HP content, however, may not have increased in proportion to the addition of collagen. Genistein may be useful for improving tendon collagen content in conditions of estrogen deficiency.
Collapse
Affiliation(s)
- J E Ramos
- Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona, USA
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Peterson A, Horak F, Martina M. P02.114. Improvement in postural response as a possible mechanism for decrease in falls with vitamin D. Altern Ther Health Med 2012. [PMCID: PMC3373760 DOI: 10.1186/1472-6882-12-s1-p170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
43
|
Soumyanath A, Denne T, Peterson A, Shinto L. P01.36. Assessment of commercial formulations of mucuna pruriens seeds for Levodopa (L-DOPA) content. BMC Complement Altern Med 2012. [PMCID: PMC3373868 DOI: 10.1186/1472-6882-12-s1-p36] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
44
|
Peterson A, Mancini M, Horak F. Improvement in Postural Response as a Possible Mechanism for Decrease in Falls with Vitamin D (P06.046). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p06.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
45
|
Peterson A, Breitner J, Kaye J, Bowman G, Baker L, Clemons A, Montine T, Quinn J. Plasma Vitamin D, Cognitive Function, and Cerebrospinal Fluid Biomarkers in Subjects at Risk of Alzheimer's Disease (P02.064). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p02.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Daniel BR, Campone M, Dieras V, Ervin T, Yu W, Paton VE, Xia Q, Peterson A. OT3-01-11: A Randomized, Phase II Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating MetMAb and/or Bevacizumab in Combination with Weekly Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot3-01-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Dysregulation of the HGF/Met pathway has been associated with tumorigenesis in many malignancies, including the basal sub-type of triple-negative breast cancer. MetMAb (RG3638) is a recombinant, humanized, monovalent monoclonal antibody directed against Met. By binding to the extracellular domain of Met, MetMAb selectively blocks ligand binding and subsequent activation by HGF. Pre-clinical data support the efficacy of combining MetMAb with numerous chemotherapy agents and with targeted agents including bevacizumab and erlotinib. In clinic, MetMAb has been generally well tolerated as a single agent (Phase I), in combination with bevacizumab (Phase Ib) and with bevacizumab in a dose escalation/expansion study (Phase Ib)1 as well as in combination with erlotinib in patients with previously treated NSCLC2. The combination of MetMAb + erlotinib in NSCLC demonstrated significant benefit in both PFS and OS in patients with Met diagnostic positive tumors whereas those patients with Met diagnostic negative tumors demonstrated a detrimental effect in both PFS and OS. The most commonly reported adverse events associated with MetMAb are peripheral edema and fatigue.
Methods: This clinical trial is a randomized three-arm Phase II study in patients with triple-negative metastatic breast cancer, which makes up the majority of basal sub-type breast cancer. Patients will be randomized (1:1:1) to either paclitaxel + bevacizumab + placebo; paclitaxel + placebo + MetMAb; or paclitaxel + bevacizumab + MetMAb. The primary endpoint of this study is PFS in all patients and by Met diagnostic status. Secondary endpoints include an evaluation of OS, ORR, safety, and pharmacokinetics. To date, 11 patients have been enrolled, and 10 patients have been treated.
Primary and secondary analyses will include all randomized patients, with patients analyzed according to the treatment arm to which they were assigned. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm. An estimate of the HR with 95% CI will be determined using a Cox regression model with an indicator variable for the MetMAb-containing arm. Safety will be assessed through summaries of adverse events and will include all patients who receive any amount of study treatment.
This study remains open for accrual; further details on the trial can be found on the ClinicalTrials.gov website under NCT01186991.
1. Moss et al, In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2–6; Orlando, FL; AACR 2011 (abstr 4717).
2. Spigel et al, J Clin Oncol 29:2011 (suppl; abstr 7505).
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-11.
Collapse
Affiliation(s)
- BR Daniel
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - M Campone
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - V Dieras
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - T Ervin
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - W Yu
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - VE Paton
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - Q Xia
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| | - A Peterson
- 1Chattanooga Oncology Hematology Associates — SCRI, Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, France; Institute Curie, Paris, France; Florida Cancer Specialists, Englewood, FL; Genentech Inc., South San Francisco, CA
| |
Collapse
|
47
|
Jenkins CC, Blackford JT, Andrews F, Frazier DL, Mattsson H, Olovsson SG, Peterson A. Duration of antisecretory effects of oral omeprazole in horses with chronic gastric cannulae. Equine Vet J 2010. [DOI: 10.1111/j.2042-3306.1992.tb04795.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Giralt A, Friedman HC, Caneda-Ferrón B, Urbán N, Moreno E, Rubio N, Blanco J, Peterson A, Canals JM, Alberch J. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther 2010; 17:1294-308. [PMID: 20463759 DOI: 10.1038/gt.2010.71] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Brain-derived neurotrophic factor (BDNF) is the main candidate for neuroprotective therapeutic strategies for Huntington's disease. However, the administration system and the control over the dosage are still important problems to be solved. Here we generated transgenic mice overexpressing BDNF under the promoter of the glial fibrillary acidic protein (GFAP) (pGFAP-BDNF mice). These mice are viable and have a normal phenotype. However, intrastriatal administration of quinolinate increased the number of reactive astrocytes and enhanced the release of BDNF in pGFAP-BDNF mice compared with wild-type mice. Coincidentally, pGFAP-BDNF mice are more resistant to quinolinate than wild-type mice, suggesting a protective effect of astrocyte-derived BDNF. To verify this, we next cultured astrocytes from pGFAP-BDNF and wild-type mice for grafting. Wild-type and pGFAP-BDNF-derived astrocytes behave similarly in nonlesioned mice. However, pGFAP-BDNF-derived astrocytes showed higher levels of BDNF and larger neuroprotective effects than the wild-type ones when quinolinate was injected 30 days after grafting. Interestingly, mice grafted with pGFAP-BDNF astrocytes showed important and sustained behavioral improvements over time after quinolinate administration as compared with mice grafted with wild-type astrocytes. These findings show that astrocytes engineered to release BDNF can constitute a therapeutic approach for Huntington's disease.
Collapse
Affiliation(s)
- A Giralt
- Facultat de Medicina, Departament de Biologia Cel·lular, Immunologia i Neurociències, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Peterson A, Quinn J. 102 BALANCE AND COGNITIVE PERFORMANCE IN PARKINSON'S DISEASE (PD). Parkinsonism Relat Disord 2010. [DOI: 10.1016/s1353-8020(10)70103-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Hernandez C, Puangsuvan SN, Peterson A, Robinson JK. Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma. Clin Exp Dermatol 2010; 34:e722-5. [PMID: 20055841 DOI: 10.1111/j.1365-2230.2009.03448.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We report an unusual case of localized cutaneous nodules heralding the recurrence of systemic CD30+ anaplastic large-cell lymphoma (ALCL). A 47-year-old woman developed numerous violaceous nodules in the perineal and upper thigh area 3 years after multimodal treatment and complete remission of primary anaplastic large-cell CD30+ lymphoma. Using immunohistochemical and T-cell gene rearrangement analysis, a recurrence of her anaplastic large-cell lymphoma was diagnosed.
Collapse
Affiliation(s)
- C Hernandez
- Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA
| | | | | | | |
Collapse
|